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CHAPTER 1. Strategies to obtain target-specific metal complexes as imaging agents 
Portions of this chapter are reprinted or adapted with permission from Vithanarachchi, S. M.; 
Allen, M. J. Current Molecular Imaging 2012, 1, 12–25. Copyright Bentham Science Publishers. 
Introduction  
Imaging techniques play a vital role in diagnostic medicine and medical research by 
aiding with the detection of diseases as well as the monitoring of disease progression and 
treatment. These imaging modalities include single photon emission computed tomography, 
positron emission tomography, ultrasound, magnetic resonance imaging (MRI), photoacoustic 
tomography, and fluorescence imaging, and reviews describing the advantages and limitations of 
each modality have been published elsewhere.
1–6
 This thesis focuses on MRI because my 
research explored the utility of Gd
III
-containing complexes to achieve targeted imaging with 
MRI. MRI is a powerful, non-invasive imaging technique that does not use ionizing radiation 
and has the capability to generate three-dimensional images of deep tissue with good spatial 
resolution (25–100 µm).6 
Conventional MRI images are produced by mapping either the relaxation rates or 
densities of the nuclear spins of water protons in a magnetic field. Differences in relaxation rates 
are due in part to the chemical composition of the surrounding environment; however, the 
inherent levels of signal intensity that result from the differences in relaxation rates of water 
protons are often not sufficient to produce satisfactory contrast. Therefore, chemicals known as 
contrast agents are used in MRI to catalytically accelerate the relaxation rate of water protons to 
obtain contrast-enhanced images. Paramagnets including Gd
III
, Mn
II
, and Mn
III
 are referred to as 
“T1-shortening agents” because of their influence on longitudinal (T1) relaxation rates, and 
superparamagnetic iron oxide (SPIO) particles are referred to as “T2-shortening agents” because 
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of their influence on transverse (T2) relaxation rates.
7
 The ability of a contrast agent to influence 
contrast is measured in terms of relaxivity, and relaxivity changes in response to changes in 
physical parameters including magnetic field strength, temperature, and solvent composition. 
This dependence of relaxivity on measurement conditions often prevents a meaningful direct 
comparison of agents in different studies. Hence, in this chapter, physical parameters are 
reported for each example to avoid misinterpretation that could arise due to direct comparison of 
agents measured under different conditions (Table 1.1). 
In current clinical MRI (1.5–3 T), GdIII-based complexes are the most commonly used 
contrast agents, and these agents are non-specific; they do not accumulate in particular tissues or 
organs of interest. Non-specific contrast agents are useful in the imaging of pathologies like 
tumors, lesions, and inflammation because these agents aid in the differentiation of healthy and 
diseased tissues based on vascular volume, vascular perfusion, and vascular permeability.
8
 While 
these non-specific contrast agents are used in ~35% of clinical scans,
9
 their utility in the early 
detection of disease and imaging of specific biological regions is limited. This limitation arises 
because diseases often do not display changes in vasculature, and if observable changes in 
vasculature occur, they are likely to occur in later stages of diseases. One method to address the 
limitation of non-specificity is the use of targeted contrast agents. Since the first descriptions of 
targeted contrast agents,
10,11
 this topic has become a focus in the field of MRI and contrast agent 
research because of the potential to enable molecular imaging in addition to anatomical imaging. 
The importance of targeted contrast agents has been described in several recent reviews.
8,3,12–18
 
These reviews discuss the development and properties of T1- and T2-shortening agents and the 
use of different biomarkers as targets. In this chapter, targeted contrast agents are described for 
proton MRI that were developed during the last ten years using two different synthetic strategies 
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with a focus on agents that have been tested both in vitro and in vivo to emphasize limitations 
that must be overcome to enable the clinical use of targeted contrast agents. 
The design of target-specific contrast agents involves two types of strategies: the most 
common strategy is to conjugate a contrast agent with an antibody, peptide, or a small organic 
molecule that enables interactions with a target. A second strategy is to transform a contrast 
agent directly into the targeting moiety by mimicking the structure of a molecule that naturally 
interacts with a desired target. The development of targeted contrast agents with these two 
strategies has led to successful targeting in vitro, and some agents have been successfully 
translated to enable in vivo visualization of targets. The remainder of this chapter is organized 
into these two strategies: conjugation and mimicking. 
 The conjugation strategy  
Direct conjugation of derivatives of clinically approved contrast agents to peptides, 
antibodies, or small organic molecules is a popular and relatively simple method of achieving 
target specificity. All directly conjugated contrast agents contain three parts: a targeting moiety, 
a contrast-enhancing unit, and a linker that connects the other two parts (Figure 1.1). When 
linking the contrast-enhancing unit and targeting moiety, either metalate-then-conjugate or 
conjugate-then-metalate methods can be used,
19
 and conjugation generally results in the 
formation of biologically stable amides, ethers, thioesters, or triazoles. Low molecular weight 
(≤30 kDa) targeted contrast agents are desirable because their small size enables diffusion to 
small areas and facile clearance, but this type of targeted contrast agent faces the challenge of 
low sensitivity: with small Gd
III
-based contrast agents, micromolar or greater concentrations are 
needed to achieve satisfactory contrast in vivo.
20, 21
 Therefore, contrast agents that possess both 
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high relaxivity and long circulation times are desirable to lower the dose of contrast agent. To 
increase sensitivity, targeting moieties and Gd
III
-containing complexes are conjugated to 
macromolecules including dendrimers, polymers, proteins, liposomes, and nanoparticles. These 
agents obtain high relaxivity by slowing the molecular tumbling rate, by combining several 
contrast-enhancing units per targeting moiety, or both. In the following section, the use of the 
conjugation strategy is described in the synthesis of targeted imaging agents using both a single 
contrast-enhancing unit (monomeric) and multiple contrast-enhancing units (multimeric), and the 
selectivity and sensitivity of the resulting agents is described for in vitro and in vivo experiments. 
 
 
 
Monomeric target-specific contrast agents 
Monomeric targeted contrast agents contain one contrast-enhancing unit per targeting 
moiety; therefore, to achieve satisfactory contrast enhancement with these agents, targets with 
high expression levels need to be selected. Examples of such highly expressed targets include 
biomarkers associated with tumors; consequently, many monomeric tumor-targeted contrast 
agents are reported. Conjugation of steroids with contrast agents enables targeting of receptors 
on tumor cells because hormone receptors are over-expressed by various tumors. 21-
Hydroxyprogesterone and 17β-estradiol are steroids that interact with progesterone receptors and 
estrogen receptors that are over-expressed by uterine, breast, ovarian, and prostate carcinomas. 
These two steroids were conjugated with Gd
III
-containing complexes to produce monomeric 
contrast agents 1.2a and 1.2b,
 
respectively (Figure 1.2).
22,23
 The relaxivity of 1.2a is 5.35 mM
–
 
Figure 1.1. Schematic representation of the basic units of targeted 
contrast agents synthesized using the conjugation strategy. 
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1
s
–1
 (1.41 T, 37 °C, and 1% dimethylsulfoxide in water), and the relaxivity of 1.2b is 6.8 mM
–1
s
–1
 
(9.4 T and phosphate buffered saline (PBS)). Because these relaxivity values are similar to those 
of clinically used non-specific agents,
20,24
 doses similar to those used for non-specific agents are 
needed to enable good contrast (0.15 mmol/kg for 1.2a and 0.075 mmol/kg for 1.2b). In vivo 
imaging of xenograft mice using intraperitoneal or subcutaneous injections of 1.2a at 7.05 T 
resulted in contrast enhancement of progesterone-receptor-positive tumors with respect to 
progesterone-receptor-negative tumors (Figure 1.3). Furthermore, agent 1.2a labels tissues that 
express progesterone receptors including the uterus and ovaries.
22
 Imaging of xenograft mice 
using 1.2b (tail-vein injection at 9.4 T) demonstrated the targeting efficiency of this agent toward 
estrogen-receptor-positive tumors by enhancing contrast relative to estrogen-receptor-negative 
tumors.
23
 The success of these two agents in enhancing contrast in tumors relies on the over 
expression of receptors in tumors relative to normal tissues. 
Integrins are other receptors targeted for imaging. Integrin-targeted contrast agents have 
the potential to enable the detection of angiogenesis and thrombosis. The cyclic peptide cRGD is 
a widely used targeting moiety for integrins.
25−27
 An αIIbβ3 integrin-receptor-targeted agent 
reported by Fayad and co-workers to detect thrombosis demonstrates the importance of high 
receptor concentration to obtain good contrast enhancement with monomeric agents.
25
 Their 
contrast agent, 1.2c, consists of cRGD conjugated to Gd
III 
1,4,7,10-tetraazacyclododecane-
N,N´,N´´,N´´´-tetraacetic acid (DOTA). This agent has a relaxivity of 9 mM
–1
s
–1
 (1.41 T and 40 
°C) and binds with the αIIbβ3 receptor as well as the αVβ3 receptor. In vivo studies with mouse 
models of thrombosis demonstrated the ability of 1.2c to increase contrast of activated platelets 
with a 0.1 mmol/kg dose injected in the tail-vein. The reason for the success of 1.2c as a 
thrombosis-targeted contrast agent is the high expression of the αIIbβ3 receptor (40,000 per 
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platelet) in platelets relative to αVβ3 (~1,500 per platelet).
28
 When the expression level of a target 
is low, larger amounts of monomeric agents are needed to achieve contrast enhancement. For 
example, cRGD-conjugated contrast agent 1.2d (Figure 1.2) was studied as a means to 
selectively image the αVβ3 integrin receptor that is over-expressed in hepatocelluler carcinomas.
27
 
The relaxivity of contrast agent 1.2d is 7.4 mM
–1
s
–1
 (1.5 T and 25 °C), and in vivo imaging of H-
ras12V transgenic mice bearing hepatocellular carcinomas at 1.5 T (tail-vein injection of 1.43 
mmol/kg of 1.2d) enhanced contrast of the tumor region. Tumor cells used in this study have a 
low concentration of αVβ3 receptors, and the contrast agent has a moderate specificity for these 
receptors; thus, the high dose used in this study was needed to saturate the receptors. 
Table 1.1. Conditions used for relaxivity measurements and MR imaging 
contr
ast 
agent 
field strength (T) tempera
ture for 
relaxivit
y (°C) 
medium for 
relaxivity 
measurements 
relaxivity 
(T1) (mM
–
1s–1) a 
relaxivity 
(T2) (mM
–
1s–1)a 
in vivo 
imaging dose 
in vitro 
imaging 
concentrat
ions 
refere
nce 
relaxivity 
measurem
ents 
in 
vivo/
in 
vitro 
studi
es 
1.2a 4.7 7.05 21 NR 4.73 NR 0.15 mmol/kg NR 22 
1.2a 1.41 7.05 37 1% DMSO in 
water 
5.35 6.14 0.15 mmol/kg NR 22 
1.2b 9.4 9.4 NR PBS 6.8 NR 0.075 
mmol/kg 
NR 23 
1.2c 1.41 9.4 40 NR 9 NR 0.1 mmol/kg NR 25 
1.2d 1.5 1.5 25 NR 7.4 4 1.43 mmol/kg NR 27 
1.2e 9.4 9.4 NR PBS 4.7 NR 0.075 
mmol/kg 
NR 23 
1.2f 4.7 4.7 NR aqueous  1.28 NR 0.2 
µmol/mouse 
0.5 mM 29 
1.2g 1.41 2 37 water  21 30 0.03 mmol/kg NR 30 
1.2h 1.41 4.7 37 Tris buffer, 
pH 7 
21 30 0.24 
µmol/mouse 
NR 31 
1.2i 0.47 NR   25 pH 7.4 7.7 NR NR NR 33 
1.2j 4.7 NR 37 water 5.5 6.9 NR NR 24 
1.2j 3 NR 37 water 5.3 6.1 NR NR 24 
1.2j 1.5 NR 37 water 5.2 5.9 NR NR 24 
1.2k 0.47 NR 37 water 5.6 NR NR NR 26 
1.2l 3 3 RT NR 4.22 4.45 0.1 mmol/kg NR 34 
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1.2m NR 7 NR NR NR NR 0.4–2 
mg/mouseb 
NR 35 
1.2n 9.4 9.4 21 water 5.2 NR 1.14 µmol/kg 0.1 mM 38, 39 
1.2n 1.41 9.4 40 water 5.1 NR 1.14 µmol/kg 0.1 mM 38, 39 
1.2n 0.47 9.4 40 water 5.8 NR 1.14 µmol/kg 0.1 mM 38, 39 
1.4a 1.41 1.5 37 TBS, pH 7.4 10.1, 40.3
c 12.8, 51.1c 4 µmol/kg NR 40, 41 
1.4a 0.47 1.5 37 TBS, pH 7.4 11.1, 44.4
c NR 4 µmol/kg NR 40, 41 
1.4b 4.7 4.7 25 PBS, pH 7.4 5.4, 16.2
c NR 0.025 
mmol/kg 
NR 43, 44 
1.4b 1.41 4.7 37 PBS, pH 7.4 16.1, 48.4
c NR 0.025 
mmol/kg 
NR 43, 44 
1.4b 0.47 4.7 37 PBS, pH 7.4 18.7, 56.2
c NR 0.025 
mmol/kg 
NR 43, 44 
1.4c 3 3 NR water 9.7 NR 5 µmol Gd/kg NR 45 
1.4d 1.5 9.4 NR water 20.6 NR 0.03 mmol 
Gd/kg 
NR 46 
1.4e 0.6 7 25 water, pH 7 29.1 NR NR ≥50 µM 47 
1.4f 3 3 NR water 64.88 NR 0.05 mmol 
Gd/kg 
NR 49 
1.4g 2 2 20 NR 26, 598
c NR 0.029 mmol 
Gd/kg 
0.01 mM 50 
1.4h 0.47 1.5 40 NR ~20, 
1,800,000c 
NR 2.7 µmol 
Gd/kg 
NR 54 
1.4i 3 3 25 water 8.2, 353
c 16.1, 692c 0.03 mmol 
Gd/kg 
NR 56 
1.4j 4.7 1.5 NR NR NR NR 3.3 µmol /kg NR 58 
1.4k 0.47 4.7 40 NR 1.04 NR 0.2 mmol 
Gd/kg 
NR 59 
1.4l 3 3 RT water  3.13, 131
c 8.74, 367c 0.03mmol 
Mn/kg 
NR 60 
1.4m 3 3 25 NR 4.1,  
~91,127c 
18.9, 
~441,120c 
NR NR 61 
1.4n 3 3 25 NR 14.6, 
~423,420c 
70.7, 
~2,135,482c 
NR NR 61 
1.4o NR 1.5 NR NR NR NR 30 µmol 
particles/kg 
0.54 mM 63 
1.4p 1.41 9.4 NR NR NR 89 0.18 mmol 
Fe/kg 
2.68 mM 64 
1.4q 3 3 NR NR 3.6 124 NR NR 65 
1.4r NR 7 NR NR NR NR NR 0.03 
mg/mL 
66 
1.4s NR 4.7 NR NR NR NR 10–16 mg/kg NR 67, 68 
1.7a 4.7 4.7 25 aqueous  8.9 NR 0.05 mmol 
Mn/kg 
NR 70 
1.7b NR 9.4 NR NR ~ 3.1
d NR 0.017–0.02 
µmol/kg 
NR 71 
1.7c 7 7 23 aqueous  16.3 20 0.1 mmol/kg NR 72 
1.7d 7 7 23 aqueous  31.7 38.2 0.1 mmol/kg NR 72 
1.7e 1.2 1.5 25 aqueous 
saline 
18 NR 0.017 
mmol/kg 
NR 82, 84 
1.7f 4.7 4.7, 
14 
NR ethanol 0.15 NR NR 1 % w/v  81 
1.7f 14 4.7, 
14 
NR ethanol 0.12 NR NR 1 % w/v  81 
1.7f 4.7, 14 4.7, NR aqueous  0.09 NR NR 1 % w/v  81 
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14 
1.7g 1.5 9.4 25 water, pH 7.4 10.4
c NR 3.25–4.36 
µmol/kg 
NR 75 
1.7h 1.41 9.4 40 NR 8.9
c 94.2c 0.54 mmol 
Fe/kg 
0.072 mM 
Fe 
76 
1.7i 1.5 1.5 NR Dulbecco’s 
PBS 
8.4c (for 
5000Fe) 
93c (for 
5000Fe) 
NR 3 mM Fe 78 
1.7j NR 11.7 NR NR NR 1–10 0.089 mmol 
Fe/kge 
NR 79 
1.7k 9.4 3, 
9.4   
NR NR 6 50 ~2.4  µmol 
Gd/kg 
NR 86 
1.7k 3 3, 
9.4 
NR NR 48 88 ~2.4  µmol 
Gd/kg 
NR 86 
1.7k 1.5 3, 
9.4 
NR NR 117 129 ~2.4  µmol 
Gd/kg 
NR 86 
NR = not reported   RT = room temperature 
a   
relaxivity per ion is reported except for those that denoted 
b
 ex vivo imaging 
c
 relaxivity per molecule or particle  
d
 estimated in vivo 
e  
five doses used 
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Figure 1.2. Monomeric targeted contrast agents synthesized using the conjugation strategy. 
Contrast agent 1.2h is adapted with permission from reference 31. Copyright 2011 Qiao et al. 
 
Figure 1.3. Representative in vivo images of targeted contrast agents: contrast enhancement of 
progesterone-receptor (PR)-positive and PR-negative tumors using monomeric conjugated 
contrast agent 1.2a. Scale bars represent 5 mm, and arrows point to tumors. Adapted with 
permission from reference 22. Copyright 2011 American Chemical Society. 
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 The integrin-receptor-targeted examples 1.2c and 1.2d demonstrate the importance of 
biomarker expression level for targeted imaging. However, in vitro success is often difficult to 
translate in vivo even with biomarkers expressed at high levels and high-affinity targeting 
moieties. For example, the estrogen-receptor-targeted contrast agent 1.2e (Figure 1.2) reported 
by Degani and co-workers has a relaxivity of 4.7 mM
–1
s
–1
 (9.4 T and PBS). However, agent 1.2e 
(using same dose as 1.2b) was not able to produce significant enhancement in vivo despite a 
higher in vitro binding affinity with a binding inhibition constant, Ki, of 0.13 µmol/L for estrogen 
receptors than 1.2b (Ki = 0.97 µmol/L).
23
 This discrepancy likely was due to the accumulation of 
1.2e in muscle tissues causing a reduction in the effective dose for estrogen-receptor-positive 
tumors. 
Further highlights of the inconsistencies that are often observed between in vitro and in 
vivo systems are exemplified by two studies that target the folate receptor, which is found in high 
concentrations in tumors. Folate-conjugated monomeric contrast agent 1.2f (Figure 1.2) has a 
low relaxivity of 1.28 mM
–1
s
–1
 (4.7 T and aqueous solution).
29
 In vitro studies of 1.2f with 
human folate-receptor-positive ovarian carcinoma (IGROV-1) cell lines did not produce signal 
enhancement; however, inductively coupled plasma-mass spectrometry results with competitive 
binding experiments confirmed the uptake of 1.2f by the cells. Despite the negative imaging 
results of the in vitro studies, in vivo studies at the same field strength demonstrated increased 
contrast of tumors in xenograft mouse models using a micromolar dose of 1.2f delivered 
intravenously. Conversely, the folate-related agent 1.2g reported by Wang and co-workers 
containing a dimeric Gd
III
 chelate conjugated to folate has a high relaxivity of 21 mM
–1
s
–1 
per 
Gd
III
 ion (1.41 T, 37 °C, and water).
30
 In vitro studies with IGROV-1 cells confirmed the uptake 
of 1.2g through folate receptors. While contrast agent 1.2g was unable to enhance contrast in 
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tumors implanted in rat models in vivo at 2 T (0.03 mmol/kg dose), the relaxation rate in the 
tumor increased and ∆R1 (the difference between the T1 relaxation rates before and 1 h after 
contrast enhancement) was 0.214 s
–1
 for 1.2g relative to non-targeted agents (0.112 s
–1
), 
suggesting that the agent was retained in the tumor. Hence, the poor enhancement obtained in 
this study likely is not related to the selectivity of the contrast agent. 
Conjugating a high relaxivity agent to a targeting moiety often is advantageous because it 
leads to an increase in contrast with lower doses of agent. Recently, Yang and co-workers 
reported contrast agent 1.2h targeted to human epidermal growth factor receptor type 2 (HER2) 
(Figure 1.2) using a designed protein chelator for Gd
III
, and agent 1.2h has a high relaxivity (21 
mM
–1
s
–1
, 1.41 T, 37 °C, and tris(hydroxymethyl)aminomethane (Tris) buffer at pH 7).
31
 The 
contrast agent is conjugated to a HER2 affibody as the targeting moiety, a fluorescent dye to 
enable tracking by fluorescence microscopy, and polyethylene glycol moieties to achieve 
biocompatibility. Agent 1.2h demonstrated increased in vivo enhancement of tumors in xenograft 
mice using a tail vein injection of 100 fold lower dose (0.24 µmol per mouse) than is used 
commonly with clinical contrast agents for routine MR imaging experiments. 
Although, a protein was used as the chelating moiety in the previous example, more often 
proteins are used as targets. There are several contrast agents that label human serum albumin, 
including Gd
III
 3,6,10,16-tetraazabicyclo[10.3.1]hexadecane-3,6,10-tris(methanephosphonates) 
1.2i, MS-325 1.2j, and Gd
III
DOTA-deoxycholic acid 1.2k (Figure 1.2).
26,32,33
 These agents bind 
to albumin leading to increased circulation times; consequently, they are used as blood pool 
imaging agents. Fibrin and collagen are other well explored proteins for targeted imaging 
because they are found in high concentrations in angiogenesis, thrombosis, atherosclerosis, and 
other wound-healing processes. The cyclic decapeptide cCGLIIQKNEC (CLT1) conjugated to 
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Gd
III
 diethylenetriaminepentaacetic acid (DTPA), 1.2l, (Figure 1.2) is a fibrin–fibronectin-
labeling agent with a relaxivity of 4.22 mM
–1
s
–1 
(3 T and room temperature).
34
 In vivo tumor 
imaging of human colon cancer xenografts in mice showed enhancement of tumors using a 0.1 
mmol/kg dose because of the high concentration of fibrin–fibronectin associated with the 
neovascularization of tumors. 
Imaging diseases in the brain is more challenging than in other parts of the body because 
of the tight regulation in transportation of compounds across the bloodbrain barrier (BBB). 
Some diseases like brain tumors disrupt the BBB allowing contrast agents to accumulate in the 
interstitial spaces that outline the tumor region. However, many other abundant neuropathologies 
including Alzheimer’s disease and multiple sclerosis do not disrupt the BBB during early stages 
of the diseases. Hence, the synthesis of targeting biomarkers to image neuropathology with MRI 
is an active area of research because of the current lack of in vivo detection methods. β-Amyloid 
peptides and myelin are two components that have been investigated as targets.
35–39
 
β-Amyloid plaques are potential biomarkers for imaging Alzheimer’s disease.35–37 A 
derivative of amyloid peptide conjugated with Gd
III
-containing complexes, 1.2m, was found to 
label amyloid plaques in vivo.
35
 MRI imaging at 7 T of brains removed from transgenic mice 
(APP-PS1) that were injected intravenously with 1.2m demonstrated contrast enhancement of 
plaques. This result implies that 1.2m has the ability to cross the BBB. However, in vivo imaging 
was not reported; hence, the applicability of 1.2m for in vivo imaging cannot be predicted 
without further research. 
Myelin is another biomarker for various neurodegenerative diseases including multiple 
sclerosis, leukodystrophies, and schizophrenia because these neuropathological disorders cause 
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either the degradation of myelin or the formation of defective myelin. Wang and co-workers 
reported myelin-targeted contrast agent 1.2n (Figure 1.2).
38,39
 Contrast agent 1.2n contains a 
coumarine derivative as the targeting unit conjugated to Gd
III
DOTA, and this agent has a 
relaxivity of 5.2 mM
–1
s
–1 
(9.4 T, 21 °C, and water). Ex vivo T1 mapping of mouse brains 
incubated with 1.2n demonstrated the specificity of 1.2n for myelin.
38
 Subsequent in vivo studies 
were carried out with intracerebroventricular infusions (~1 mg (1.14 μmol)/kg) because of the 
poor BBB penetration of 1.2n. These studies demonstrated the specificity for myelin and the 
ability of 1.2n to highlight demyelination with T1 mapping at 9.4 T.
39
 However, conventional 
MR imaging was not reported with this agent, which likely was due to low sensitivity that needs 
to be improved for clinical translations of 1.2n. 
While monomeric agents are desirable because of their low molecular weight, in general, 
studies of monomeric targeted agents reveal the need for biomarkers with high local 
concentrations or for the use of large doses of contrast agents to achieve enhancement of targets 
due to the low sensitivity of these agents. Therefore, it is essential to increase the sensitivity of 
target-specific agents to image biomarkers with relatively low expression levels. 
 Multimeric target-specific contrast agents 
Compared to monomeric agents, multimeric contrast agents can be used to image 
biomarkers that have relatively low expression levels. Also, the blood circulation of multimeric 
contrast agents tends to be longer than that of monomeric agents because the large size of 
multimeric agents prevents rapid clearance via the kidneys; hence, multimeric agents often have 
a longer time to interact with targets. Furthermore, high molecular weights result in slow 
tumbling rates that increase relaxivity, and multimeric targeted contrast agents contain up to 
14 
 
thousands of contrast-enhancing units and targeting moieties that also increase relaxivity. The 
long circulation times and high relaxivities of multimeric agents enable the use of smaller doses 
than monomeric agents for in vivo imaging. 
Fibrin-targeted agent 1.4a (Figure 1.4) contains four Gd
III
DOTA complexes conjugated 
to an 11-amino-acid fibrin-targeting peptide. The relaxivity of this tetrameric contrast agent is 
10.1 mM
–1
s
–1 
per Gd
III 
ion in the absence of fibrin and increases to 17.8 mM
–1
s
–1 
per Gd
III
 ion 
upon binding to fibrin (1.41 T, 37 °C, and Tris buffered saline (TBS)).
40
 The effectiveness of 
1.4a as a targeted contrast agent in vivo was demonstrated by imaging pulmonary emboli and 
cerebral venous sinus thrombosis.
41,42
 Both studies were performed using swine models 
containing engineered human blood clots, and contrast enhancement was reported at 1.5 T after 
intravenous injection of 4 µmol/kg of 1.4a. These studies reveal the specificity of 1.4a for fibrin 
and the applicability of 1.4a to the detection of fibrin-associated diseases in vivo with low doses. 
 A structurally similar agent to 1.4a is collagen-targeted contrast agent 1.4b (Figure 1.4). 
Agent 1.4b was synthesized by conjugating three Gd
III
DTPA complexes to a 16-amino-acid 
peptide.
43
 Contrast agent 1.4b has a relaxivity of 16.1 mM
–1
s
–1 
per Gd
III
 ion
 
(1.41 T, 37 °C, and 
PBS) or 5.4 mM
–1
s
–1
 per Gd
III
 ion (4.7 T, 25 °C, and PBS). In vivo imaging with 1.4b (tail-vein 
injection of 0.025 mmol/kg) in mouse models enabled specific imaging of myocardial fibrosis at 
4.7 T.
43,44
 The higher dose used for 1.4b relative to 1.4a, is likely necessary due to the large 
amounts of collagen present in many organs and low relaxivity reported for 1.4b at 4.7 T field 
strength. With agents 1.4a and 1.4b, three or four Gd
III
-containing units were conjugated to the 
targeting peptide via functional groups present in the amino acid side chains resulting in 
increased efficiency. 
15 
 
  To increase relaxivity by increasing Gd
III
-loading, macromolecules including polymers, 
dendrimers, nanoparticles, and liposomes are used.
45–60
 These macromolecules act as carriers to 
transport large numbers of contrast agents and targeting moieties. The expectation with this 
method is that contrast enhancement will be observed even if only a small number of target 
molecules are labeled. Conjugation of several Gd
III
-containing complexes and targeting moieties 
to poly(L-glutamic acid)cystamine or N-(2-hydroxypropyl)methacrylamide produced contrast 
agents 1.4c and 1.4d (Figure 1.4) for targeting integrins.
45,46
 Agent 1.4c  has a relaxivity of 9.7 
mM
–1
s
–1 
per Gd
III
 ion
 
(3 T and water) and 1.4d has a relaxivity of 20.6 mM
–1
s
–1 
per Gd
III
 ion
 
(1.5 
T and water). Both agents effectively bind αVβ3 intergrin in vitro, and quantitative T1 mapping 
demonstrated that polymers 1.4c and 1.4d interact with integrins in the tumors of xenograft mice 
using tail-vein injections of 5 µmol Gd
III
/kg and 0.03 mmol Gd
III
/kg, respectively. However, a 
contrast enhancement was not observed with 1.4c  or 1.4d, which likely was due to insufficient 
loading of Gd
III
-containing complexes onto the polymers.
45,46 
Another type of macromolecular targeting agent uses proteins as scaffolds for targeting 
moieties and Gd
III
-containing chelates. Maleylated bovine serum albumin conjugated to 
Gd
III
DOTA, 1.4e, was studied as a macrophage-scavenger-receptor-targeted contrast agent in 
vitro.
47
  The maleyl groups acted as the targeting moieties and up to 22 Gd
III
-chelates were 
linked to the protein. The relaxivity of 1.4e is 29.1 mM
–1
s
–1
 per Gd
III
 ion (0.61 T, 25 °C, and 
water at pH 7), and in vitro cell imaging demonstrated increased contrast for macrophages after 
incubation with 1.4e. 
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Figure 1.4. Multimeric targeted contrast agents synthesized using the conjugation strategy. 
Contrast agents 1.4i, 1.4j, 1.4l, 1.4p, and 1.4r were adapted with permission from references 
56, 58, 60, 66. Copyright 2010 American Chemical Society; and 64. Copyright 2010 Wiley-
VCH verlag GmbH & Co. KGaA, Weinheim, respectively. 
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Dendrimers are also used as carriers for multimeric agents. Polyamidoamine (PAMAM) 
dendrimers are widely used as a macromolecular delivery system because they can be 
functionalized easily and are biocompatible.
48–50
 In vivo imaging using agents 1.4f and 1.4g 
composed of folic acid and Gd
III
-containing chelates conjugated to PAMAM dendrimers enabled 
contrast enhancement of human epidermoid carcinomas in xenograft mice.
49,50
 The relaxivity of 
these contrast agents is higher than monomeric agents, for example 64.88 mM
–1
s
–1
 per Gd
III
 ion 
(3 T and water) for 1.4f and 26.0 mM
–1
s
–1
 per Gd
III
 ion (2 T and 20 °C) for 1.4g. These high 
relaxivities enable low-dose imaging (tail-vein injections of 0.05 mmol Gd
III
/kg and 0.029 mmol 
Gd
III
/kg for 1.4f and 1.4g, respectively). 
Nanoparticles and liposomes that contain Gd
III 
chelates are other classes of multimeric 
targeted contrast agents. These systems enable the incorporation of different types of imaging, 
therapeutic, and targeting agents to the same carrier without great synthetic burden. Tens to 
thousands of Gd
III
 or Mn
II 
ions have been loaded into nanoparticles for use as targeted contrast 
agents for in vitro and in vivo studies.
54,56,57
 Lanza and co-workers reported integrin-targeted 
contrast agents for tumor imaging using Gd
III
-containing nanoparticles.
54,55
 These nanoparticles, 
1.4h, containing an αVβ3 integrin antagonist and Gd
III
DTPA, were used to visualize early tumor 
angiogenesis in xenograft mice using intravenous injections of 0.5 mL/kg (~0.03 nmol 
particles/kg or 2.7 µmol Gd
III
/kg based on data in [54]). Each nanoparticle contained ~90,000 
Gd
III
 ions with a relaxivity of 1,800,000 mM
–1
s
–1
 per particle (~20 mM
–1
s
–1
 per Gd
III
 ion, 0.47 T, 
and 40 °C). Nanoparticle 1.4h produced a 173% contrast enhancement in melanoma xenografts 
at 1.5 T.
54
 Lu and co-workers recently reported a nanoglobular system 1.4i (Figure 1.4) 
containing the decapeptide CLT1 and Gd
III
DOTA to target fibrin–fibronectin.56 The generation 3 
nanoglobular system with a molecular relaxivity of 353 mM
–1
s
–1
 (8.2 mM
–1
s
–1
 per Gd
III
 ion) (3 
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T, 25 °C, and water) was used for in vivo imaging of tumor-bearing mice. A tail-vein injection of 
0.03 mmol Gd
III
/kg of 1.4i produced image enhancement in the area of the tumor (Figure 1.5). 
The nanoparticles were excreted via the renal pathway, which is important for the translation of 
these contrast agents into clinical applications. 
 
 
 
 
 
Although, nanoparticles are potential carriers to increase the local concentration of 
contrast agent at sites of interest, maintaining a size smaller than the renal excretion threshold 
(~8 nm) and a high relaxivity is needed to enable the clinical application of these agents. To 
achieve high relaxivity with nanoparticles, attachment of Gd
III
-containing chelates
 
to the surface 
of nanoparticles is more desirable than encapsulation
57
 because encapsulation decreases 
relaxivity of nanoparticles. For example, Gd
III
DOTA encapsulated in chitosan nanoparticles 1.4j 
(Figure 1.4) and Gd
III
DTPA encapsulated in liposomes 1.4k have lower relaxivities (1.04 mM
–
1
s
–1
 per Gd
III
 ion, 0.47 T, and 40 °C for 1.4k) than Gd
III
DOTA and Gd
III
DTPA, respectively.
58,59
 
These low relaxivities resulted from the reduced accessibility of water molecules to the Gd
III
 ions 
due to the encapsulation inside of the hydrophobic nanosystems. Attaching Gd
III
-containing 
chelates on particle surfaces enables facile access of water molecules to Gd
III
 ions; however, 
 
Figure 1.5. Representative in vivo images of targeted contrast agents: contrast enhancement 
of fibronectin–fibrin complex in tumor tissues using multimeric conjugated contrast agent 
1.4i. Arrows point to tumors. Reprinted with permission from reference 56. Copyright 2010 
American Chemical Society. 
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attaching a large number of Gd
III
-containing chelates on the nanoparticle surface increases the 
risk of leaching Gd
III
 ions. 
 Because of the toxicity of unchelated Gd
III
 ions, several research groups have studied 
Mn
II
-containing nanosystems for targeted imaging.
60,61
 Although, Mn
II
 (spin 5/2) has a lower 
relaxivity than Gd
III
 (spin 7/2), nanosystems with large Mn
II
 loadings can produce contrast 
enhancement of targets. Lu and co-workers reported a nanoglobular system 1.4l (Figure 1.4) that 
contained the fibrin-targeted decapeptide CLT1 and Mn
II
DOTA monoamide.
60
 This Mn
II
 
nanosystem has a relaxivity of 3.13 mM
–1
s
–1 
per Mn
II
 ion and 131 mM
–1
s
–1 
per nanoglobule (3 T 
and room temperature). In vivo imaging of breast carcinoma xenograft mice that were injected 
(tail-vein) with 0.03 mmol Mn
II
/kg of 1.4l produced contrast enhancement of tumor with respect 
to non-targeted controls, and the contrast agents were excreted through the kidneys. Manganese 
oxide nanocolloidal systems also were reported to target fibrin.
61
 Mn
II
 oxide nanocolloide 1.4m 
and Mn
II
 oleate nanocolloide 1.4n both labeled fibrin clots in vitro. The relaxivities of 1.4m and 
1.4n were 4.1 and 14.6 mM
–1
s
–1
 per Mn
II
 ion (91,127 and 423,420 mM
–1
s
–1
 per particle at 3T, 25 
°C), respectively. These high relaxivity values and in vitro studies suggest that Mn
II
 oxide 
nanocolloides could be useful for in vivo fibrin detection. 
Superparamagnetic target-specific contrast agents using the conjugation strategy 
Superparamagnetic iron oxide (SPIO) nanoparticles coated with polymers are another 
class of contrast agents for MRI. These agents enhance the contrast of images by decreasing 
signal intensity in T2- and T2
*
-weighted imaging and, consequently, darkening the target area 
relative to surrounding tissues. Although, the darkening effect (negative contrast) is not ideal for 
anatomical imaging, many SPIO-based target-specific contrast agents are reported with T2-
20 
 
weighted imaging because they can be used for target detection in post-injection images when 
compared to pre-injection images. Additionally, SPIO-based images can be converted to positive 
imaging agents using different pulse sequences and post-processing positive-contrast 
techniques.
62
 Although, these new positive imaging techniques with SPIO nanoparticles have 
been reported with cell labeling and tracking studies, we have limited our discussion on SPIO-
based target-specific contrast agents in this section to conventional  T2- or T2
*
-weighted imaging. 
SPIO nanoparticles are used in MRI because of the biocompatibility of iron oxide 
nanoparticles and high T2 relaxivity for contrast enhancement. These biocompatible SPIO 
nanoparticles are taken up by the reticuloendothelial system (RES) in cells; hence, in early 
studies, SPIO nanoparticles were used to detect lesions in RES-rich organs including the liver, 
spleen, and lymph nodes without the use of a conjugated targeting moiety.
17
 However, recent 
research has focused on conjugating targeting moieties to the nanoparticle surface to achieve 
selectivity to areas other than hepatic lesions. Conjugation of targeting moieties to the iron oxide 
core is possible because of the polymeric coatings used to stabilize the SPIO nanoparticles. 
Rajabi and Tsourkas and co-workers reported the use of targeted SPIO nanoparticles for 
selective detection of tumors in vivo.
63,64
 The contrast agents reported by these groups target the 
HER2 receptor in tumor tissues and consisted of magnetic nanoparticles modified with the 
monoclonal antibody Trastuzumab, 1.4o, or with a HER2-affibody, 1.4p (Figure 1.4). To 
synthesize particle 1.4o, the targeting antibody was conjugated to the nanoparticle using an 
amine-containing linker incorporated into a dextran coating.
63
 Whereas, in particle 1.4p, the 
azide–alkyne Huisgen cycloaddition (often referred to as “click” chemistry) was used to 
conjugate an alkynated linker containing the HER2-targeted affibody to a polymer coating 
functionalized with azides.
64
 Agent 1.4o enhanced the tumor regions in mouse models relative to 
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surrounding tissues with 30 µmol/kg (tail-vein injections). For agent 1.4p, a 10 mg (0.18 mmol) 
Fe/kg dose was used (retro-orbital injection) to enhance contrast of tumors (Figure 1.6). Iron 
oxide nanoparticles conjugated with urokinase-type plasminogen activator (uPA) peptide, 1.4q, 
used carboxylates on the polymer coating to conjugate with targeting moieties.
65
 The uPA 
peptide was engineered to contain an amine that enables conjugation with nanoparticles via 
amide linkages. Contrast agent 1.4q has relaxivity (T2) value of 124 mM
–1
s
–1 
(3 T) and targets 
uPA receptors that are over-expressed in tumors. In vivo imaging with intravenous injections of 
1.4q at 3 T using mammary carcinoma bearing mouse models demonstrated enhanced contrast in 
the tumor region, but contrast enhancement within the tumor was heterogeneous. This 
heterogeneous distribution of 1.4q in tumor tissue and the resultant decrease in signal intensity 
enabled an understanding of receptor distribution in addition to tumor detection. Another cancer-
cell-targeted SPIO-nanopartcle-based contrast agent, 1.4r (Figure 1.4), acts as a drug delivery 
vehicle as well as an imaging probe.
66
 In this study, SPIO nanoparticles were labeled with a 
monoclonal antibody, a fluorescent probe, and four anticancer drugs that release from the SPIO 
nanoparticle in response to changes in pH. Although, in vivo imaging was not performed, in vitro 
studies of this potential theranostic agent using human colon cancer cells (LS174T) demonstrated 
a reduction of T2 in cells incubated (0.03 mg/mL and 37 °C) with 1.4r (55.5 ms) with respect to 
untreated control cells (117.3 ms) at 7 T. 
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Other than tumor imaging, SPIO nanoparticles are reported to detect renal inflammations. 
Thurman and co-workers reported the use of SPIO nanoparticles, 1.4s, conjugated with a 
recombinant protein that targets the complement receptor type 2 in kidneys for in vivo studies of 
glomerulonephritis. A dose of 10–16 mg of particles/kg enhanced contrast of the kidneys of 
diseased mice and demonstrated the potential for selective visualization of renal inflammation 
without the need for invasive renal biopsies.
67,68
 
  The direct conjugation of targeting moieties with contrast agents or carrier molecules 
containing contrast agents is synthetically a simple approach to achieve selectivity. Therefore, 
both in vitro and in vivo imaging are reported for many targeted agents synthesized with this 
strategy. Monomeric targeted agents interact with or are internalized by targeted cells and can 
clear from the body easily because of their small size. But, monomeric agents often have low 
sensitivity. Multimeric agents that bear up to thousands of contrast-enhancing units and targeting 
moieties have high relaxivities because of their large size and the number of conjugated contrast 
agents. However, large size can result in difficulties in clearance. Therefore, while each class of 
targeted agents has potential niche uses, multimeric agents of intermediate size that have high 
 
Figure 1.6. Representative in vivo images of targeted contrast agents: contrast enhancement of 
HER2-positive tumors using conjugated SPIO nanoparticle 1.4p. Arrows point to tumors. 
Adapted with permission from reference 64. Copyright 2010 Wiley-VCH Verlag GmbH & 
Co. KGaA, Weinheim. 
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relaxivities but remain within the renal-clearance threshold likely will be the agents with more 
potential for in vivo applications in the future. 
Target-specific contrast agents designed with the structure-mimicking strategy 
Transforming contrast agents into structural mimics of molecules that interact with 
specific tissues and receptor molecules is a targeting strategy that converts contrast agents 
directly into targeting moieties. However, the synthesis of contrast agents that mimic the 
structure of biologically active molecules can be synthetically challenging. Several attempts to 
synthesize targeted biomimetic contrast agents have been reported and include porphyrin-, high-
density-lipoprotein-, and ferritin-based agents.
69–79
 
Porphyrins selectively accumulate in necrotic tissues and interact with neurons;
69,80,81
 
porphyrins also form stable complexes with some metal ions and possess optical properties that 
are advantageous for imaging studies. Consequently, several porphyrin-based contrast agents 
have been reported for tumor targeting. Mn
III
-containing porphyrin–dextran system 1.7a (Figure 
1.7) was used to visualize tumors in vivo. Porphyrin agent 1.7a has a relaxivity of 8.90 mM
–1
s
–1
 
(4.7 T and aqueous solution) and enhances tumor contrast in mice bearing hepatoma tumors 
using a 0.05 mmol Mn
III
/kg dose (intravenous injection).
70
 Another Mn
III
-based porphyrin, 1.7b 
(Figure 1.7), was reported as a brain-tissue-specific contrast agent that is cell permeable and 
labels neuronal cell bodies in the hippocampus.
71
 However, the introduction of contrast agent 
1.7b to rat brains (0.017–0.02 µmol/kg dose) using direct injection and the long retention time 
reported in brain tissues (t1/2 ≈ 10 days) suggest areas for future research with this contrast agent. 
Although, Mn
III
-containing porphyrins have higher relaxivities than clinical contrast 
agents, they have lower relaxivities than Gd
III
-containing porphyrins.
70,72
 Two Gd
III
-containing 
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porphyrins 1.7c and 1.7d (Figure 1.7) were reported for in vivo melanoma imaging (relaxivities 
of 16.3 and 31.7 mM
–1
s
–1
 at 7 T, 23 °C, and aqueous solutions for 1.7c and 1.7d 
respectively).
72,73
 In vivo imaging of xenograft nude mice using 0.1 mmol/kg of 1.7c and 1.7d 
(intravenous bolus injections) showed contrast enhancement in tumors due to specific 
accumulation.
72
 However, Gd
III
-containing porphyrins are kinetically unstable in solution 
because of the size disparity between the cation and porphyrin cavity.
74,82
 Hence, expanded 
porphyrin systems, such as texaphyrins, are used to form stable complexes with Gd
III
. Like 
porphyrins, Gd
III
-containing texaphyrins accumulate in tumors and enhance contrast.
83
 The 
relaxivity of Gd
III
-containing texaphyrin 1.7e (Figure 1.7) is 18 mM
–1
s
–1 
(1.2 T, 25 °C, and 
aqueous saline).
84
 Because of the specific accumulation of texaphyrins in tumors and the optical 
properties of these molecules, texaphyrins are used as radiation sensitizers for tumor therapy and 
as tumor-specific imaging probes.
85
 
Another porphyrin structural mimic used as a targeted contrast agent is the copper 
phthalocyanine dye Luxol fast blue MBS (LFB MBS) 1.7f (Figure 1.7). Complex 1.7f is a 
histology stain for myelinated neurons that was studied as a contrast agent for MRI in ex vivo 
brain tissues.
81
 The relaxivity of this agent is low (0.15 mM
–1
s
–1
, 4.7 T, and ethanol) partially 
because the Cu
II
 ion has a spin of 3/2. Heavily myelinated regions appeared brighter in images 
when stained with LFB MBS with respect to control experiments, but to attain good contrast 
enhancement, similar molecules containing metals with higher spin values need to be 
synthesized. 
Synthetic high-density lipoprotein (HDL) nanoparticles are another class of targeted 
contrast agents that mimic natural molecular entities to achieve selectivity. HDL particles are 
made into contrast agents by incorporating chelated Gd
III
 into the outer phospholipid coating or 
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by loading the core of the HDL particle with iron oxide.
75,76
 Synthetic HDL nanoparticles 1.7g 
and 1.7h (Figure 1.7) target atherosclerosis. In vivo imaging of genetically engineered 
hyperlipidemic (ApoE KO) mice with tail-vein injections of 3.25 and 4.36 µmol/kg doses of 1.7g 
(relaxivity (T1) of 10.4 mM
–1
s
–1 
per particle, 1.5 T, 25 °C, and water at pH 7.4) demonstrated 
contrast enhancement of plaques (Figure 1.8).
75
 In vivo imaging of ApoE KO mice with 1.7h 
(relaxivity (T2 ) of 94.2 mM
–1
s
–1
, 1.41 T, and 40 °C) also demonstrated contrast enhancement of 
plaques using 30 mg (0.54 mmol) Fe/kg.
76
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Another iron-oxide-containing biomimetic used as a targeted agent is ferritin. Ferritin is a 
protein that stores iron and regulates levels of iron in the body. Consequently, endogenous 
ferritin can be used to recognize some ferritin-related diseases using MRI.
77
 Thus, ferritin 
provides a template to generate SPIO-based contrast agent mimics. Recombinant human H chain 
 
 
Figure 1.7. Targeted contrast agents synthesized using the structure mimicking strategy. 
Contrast agents 1.7g, 1.7h, and 1.7k were adapted with permission from references 75, 78, 
and 86. Copyright 2004 and 2008 American Chemical Society. 
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ferritin, 1.7i, was used in vitro as a macrophage-targeted contrast agent, and these studies showed 
selective uptake of 1.7i by macrophages (incubated with 165 µg (3 µmol) Fe/mL of 1.7i) 
resulting in contrast enhancement at 1.5 T.
78
 In another study, cationic ferritin 1.7j was used as a 
basement-membrane-selective contrast agent to detect glomerulosclerosis.
79
 Both ex vivo and in 
vivo imaging using 1.7j in rat models at 11.7 T detected disruptions of basement membranes; 
however, five intravenous injections of a relatively high dose (~5 mg (0.089 mmol) Fe/kg) was 
required to detect cationic ferritin accumulation in glomeruli in vivo: this high dose is a challenge 
for translation into clinical applications. 
 
 
 
 
 
 
 Recently, Yang and co-workers reported engineered proteins that chelate Gd
III 
ions to 
produce stable high relaxivity contrast agents for MRI.
86
 An example is a contrast agent 
containing an engineered cell adhesion protein 1.7k (Figure 1.7) with a domain to chelate Gd
III
 
ions. Agent 1.7k has a relaxivity of 117 mM
–1
s
–1
 (1.5 T) enabling doses as low as 2.4 µmol 
Gd
III
/kg for contrast-enhanced imaging. Using this approach, endogenous proteins can be 
mimicked to synthesize targeted contrast agents with higher efficiency. 
 
Figure 1.8. Representative in vivo images of targeted contrast agents: contrast enhancement 
of atherosclerotic plaques using high-density lipoprotein mimic 1.7g. Arrows point to 
abdominal aorta. Adapted with permission from reference 75. Copyright 2004 American 
Chemical Society. 
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While the structure-mimicking strategy enables the use of endogenous interactions to 
deliver agents, synthesizing targeted agents with the structure-mimicking strategy is challenging 
and not generalizable like the conjugation strategy. Therefore, the scope of targets and number of 
examples are limited relative to agents synthesized with the conjugation strategy. Some of these 
agents have high relaxivities and enhance contrast in vivo; however, more research is needed in 
this area to improve current mimetic agents and to find new biomimetics that form stable 
paramagnetic complexes and are specific for various tissues and diseases. 
Summary 
Targeted contrast agents enable the visualization of structural changes in organs or the 
expression of biological molecules, and these agents have the potential to aid in the diagnosis of 
diseases at early stages. In general, targeting ability is achieved by conjugating a targeting 
moiety to a contrast agent or by mimicking the structural features of targeting moieties with 
contrast agents. A large number of targeted agents have been synthesized with the conjugation 
strategy, and while conjugation of a single contrast-enhancing unit per targeting moiety enables 
selective imaging in the presence of high local concentrations of targets, many such contrast 
agents suffer from low sensitivity and require large doses to achieve contrast enhancement. The 
use of multiple contrast-enhancing units in multimeric agents overcomes the limitation of 
sensitivity, but the large size of multimeric agents can cause difficulties with excretion. Synthesis 
of macromolecules smaller than the renal excretion threshold is a strategy to avoid this problem, 
but this strategy also influences relaxivity. Also, polydispersity of these systems can lead to 
difficulties with reproducibility. Relatively few examples of the mimicking strategy are reported 
for the design of targeted contrast agents because of the limited availability of biomimetics that 
form stable complexes with paramagnetic cations; however, recent advances in nanochemistry 
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and biotechnology will likely lead to more opportunities for mimicking biologically important 
structures with contrast agents. 
Except for one or two target-specific contrast agents that are clinically approved (MS-
325) or in clinical-trials (texaphyrins), the majority of target-specific agents are in pre-clinical 
levels of research; however, successful in vivo imaging was reported with many pre-clinical 
studies, and these results shine positive light onto the future of the field. An area of where extra 
attention to detail will likely aid the field is the inclusion of as many experimental details as 
possible: the direct comparison of different studies is difficult because the conditions used for 
relaxivity measurements and imaging experiments are different (Table 1.1), and improper 
comparisons could lead to misinterpretations of the efficiency of one agent compared to another. 
Finally, improvements to the selectivity, sensitivity, and biocompatibility of target-specific 
agents and the selection of new molecular targets using both the conjugation and mimicking 
strategies will likely enable translation into clinical applications for MRI. 
Focus and layout of this thesis  
 The focus of the research described in this thesis is the exploration of the utility of Gd
III
-
containing complexes to achieve targeted imaging with MRI. The two targets that were selected 
were myelin and β-amyloid plaques, which are important markers for detection of neurological 
disease as described earlier in this chapter. The ability to detect neurological disease without 
ambiguity is important for clinical imaging where early detection is essential for better treatment, 
and also for the advancement of related research. The findings of the research in this thesis 
would be mostly important for pre-clinical research related to neurological disease because these 
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studies lead to ex vivo and in vitro targeted imaging of myelin and β-amyloid aggregates, 
respectively. 
To achieve the target specificity with Gd
III
-containing complexes, both the conjugation 
and structure mimicking synthetic strategies that introduced previously in this chapter were used. 
The Gd
III
-containing complex that was used to achieve the targeting of β-amyloid aggregates was 
synthesized using conjugation strategy, and the Gd
III
-containing complexes for targeting myelin 
were synthesized using structure mimicking strategy. In Chapter 2, the design and synthesis of 
each metal complex is detailed including a discussion of the features of the new designed 
complexes that are important to achieve target specificity. In Chapters 3 and 4, the experiments 
are described that establish the ability of these complexes to act as target-specific contrast agents.  
In Chapter 5, the results reported in Chapters 2–4 are summarized in the context of other 
reported contrast agents and includes a discussion of suggested future directions for this research.  
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CHAPTER 2. Ligand design and synthesis 
Introduction  
Target-specific metal complexes can be achieved using two synthetic strategies, either 
conjugation or structure mimicking, as described in  Chapter 1. To obtain efficient targeting and 
imaging, these metal complexes need to fulfill several requirements regardless of the synthetic 
strategy that is being used, including (1) enabling interaction with the target, (2) maintaining 
kinetic stability under the conditions of imaging, (3) having no interference of function between 
the targeting and imaging components, and (4) being synthetically feasible. Thus, addressing 
these requirements is an essential step in ligand design to achieve efficient target-specific 
contrast agents.  The metal complexes presented in this thesis as contrast agents for magnetic 
resonance imaging (MRI) were designed to fulfill these four requirements. The following 
sections describe the design, synthesis, and the characterization of the metal complexes.   
Design and synthesis of a β-amyloid-targeted metal complex. 
The β-amyloid-targeted metal complex 2.1 was designed to be synthesized using the 
conjugation strategy, specifically by conjugating a small molecule known to have affinity for -
amyloid plaques to a derivative of a Gd
III
-based contrast agent. The -amyloid-plaque-selective 
small molecule that was chosen is curcumin, 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione (Figure 2.1a).  Curcumin is a compound found in the rhizomes of the plant 
Curcuma longa, and it is a relatively hydrophobic, fluorescent molecule that is non-toxic at gram 
dosages.
87
 Curcumin is known to interact with amyloid fibrils, and the planar hydrophobic 
aromatic structure of the molecule is considered to be the key feature for its interaction with β-
amyloid fibrils.
88
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The β-pleated structure of aggregated amyloid protein allows small planar hydrophobic 
molecules to intercalate among β-pleated 
sheets and aromatic residues in the protein, 
leading to specific retention of these 
molecules in amyloid plaques. Therefore, 
curcumin is a good candidate for a targeting 
moiety for β-amyloid aggregates with its 
planar, hydrophobic, and non-toxic 
properties. Furthermore, synthetic curcumin 
is commercially available, and there are several functional groups found in curcumin including 
phenols and a β-ketoenol that can be used for conjugation reactions.  
The contrast agent that was chosen for the conjugation is a Gd
III
-containing complex of 
diethylenetriaminepentaacetic acid functionalized with an isothiocyanate group (Gd
III
DTPA-
BnSCN) (Figure 2.1b). Gd
III
DTPA is a clinically approved contrast agent for MRI, and the 
isothiocyanate group imparts the ability to conjugate to various nucleophilic functionalities. 
Furthermore, benzyl-isothiocyanate-containing DTPA is commercially available.  
Initial design of the metal conjugate included a direct conjugation of the isothiocyanate 
group to the activated α-carbon of the β-ketoenol. To synthesize the conjugate, the phenols were 
first protected with benzoyl chloride and then two different sets of reaction conditions were tried 
to accomplish the desired reaction. The first attempt included the reaction of benzoyl-protected 
curcumin with Gd
III
DTPA-BnSCN in dimethylsulfoxide in the presence of KOH following 
published procedures for the conjugation of similar functional groups.
89
  The second attempt 
included the reaction of benzoyl-protected curcumin with sodium ethoxide to form the sodium 
Figure 2.1. Chemical structures of  (a) curcumin 
and (b) Gd
III
DTPA-BnSCN. 
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salt of enolate of 2.1a and subsequent reaction of with Gd
III
DTPA-BnSCN in pyridine. These 
reaction conditions did not result in the desired conjugate based on mass spectrometric analysis. 
The reason that avoided the occurrence of the reaction assumed to be the steric hindrance caused 
by DTPA molecule. Because direct conjugation of the curcumin molecule to the isothiocyante 
group in Gd
III
DTPA-BnSCN was not successful, the targeted complex was redesigned by 
introducing an amine containing arm to the curcumin molecule.     
The rationale behind the introduction of an amine linker included facilitating the reaction 
of Gd
III
DTPA-BnSCN with curcumin and incorporating space between the targeting moiety and 
the imaging unit to avoid potential interference of function. The amine linker was synthesized 
using a published procedure
90
 and was introduced to one of the phenol groups using sodium 
methoxide in methanol. The isolated amine-linker-containing curcumin was conjugated to 
Gd
III
DTPA-BnSCN in the presence of diisopropylethylamine (DIEA) in aqueous acetonitrile 
(Scheme 2.1).  
             
             
             
             
             
             
             
             
    
Scheme 2.1. Synthetic route to β-amyloid-targeted curcumin-conjugated GdIII-containing 
complex 2.1. 
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Design and synthesis of myelin-targeted metal complexes 
 Myelin-targeted metal complexes were designed to be synthesized using the structure 
mimicking strategy. A known myelin-specific histology stain, luxol fast blue MBS (LFB MBS), 
was selected as the template molecule (Figure 2.2).  LFB MBS was found to be a stain for 
myelin in 1953 by Klüver and Barrera 
based on the knowledge that porphin 
derivatives are able to bind with myelin 
and that the phthalocyanine ring is similar 
in structure to porphyrins.
91 
Although it is 
known that LFB MBS is capable of 
staining myelin, the site of interaction and nature of the interaction is unknown. However, 
several potential sites of interaction have been suggested:  phospholipids, neurokeratin, 
proteolipid proteins, lipoproteins, and myelin basic proteins.
81 
 From these potential sites, the 
acid–base type of interaction between LFB MBS and myelin basic protein is more accepted due 
to the removal of ditolylguanidinium cation from stain upon  interaction.
92
 The planar non-polar 
structure of the LFB MBS is assume to facilitate the diffusion of LFB MBS into the myelinated 
regions in tissue, thus facilitating the interaction between the sulfonate groups of LFB MBS and 
the basic proteins containing cationic amino acids such as arginine. Despite functional 
knowledge of the myelinLFB MBS interaction being limited, LFB MBS was used as the 
template molecule to design a myelin-targeted contrast agent in this research because its structure 
includes a macrocyclic ligand coordinated to a metal, and this motif is amenable to adaptation 
into a contrast agent for MRI. The texaphyrin ligand (Figure 2.3) was selected to design a 
Figure 2.2.  Structure of  LFB MBS stain 
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complex containing the Gd
III 
ion by mimicking the structural features of the phthalocyanine 
ligand of LFB MBS. Of the chelating ligands for trivalent lanthanide cations that have been   
reported in the literature, the texaphyrin 
macrocycle shows a good potential to 
mimic the LFB MBS ligand fulfilling 
the requirements mentioned at the 
beginning of this chapter, namely, the 
ability to form a stable complex with 
Gd
III
, good relaxivity that is essential 
for imaging, and synthetic feasibility. 
Structural similarities of phthalocyanine and texaphyrins include 22π Hückel aromatic systems, 
pyrrolic nitrogen donor atoms, and a planar macrocyclic structure.
 
Additionally, the potential to 
introduce functional groups to the side chains of texaphyrins allows further mimicking of the 
LFB MBS structure. Using the texaphyrin ligand core, six different paramagnetic metal 
complexes, 2.2–2.7, were designed to study the effect of charge and acid functional groups on 
myelin binding (Figure 2.4). 
 The functional groups incorporated in these designed molecules include esters, 
sulfonates, and carboxylates. All these functional groups have oxygen donor atoms, and 
sulfonates and carboxylates carry negative charges. Sulfonates were chosen to exactly mimic the 
functional group in LFB MBS, and carboxylates were chosen to investigate if the acid group 
needs to be sulfonates. Methyl esters were chosen to study the need for acid functional groups. 
Additionally, the methyl ester containing texaphyrin is an intermediate in the synthesis of  the  
carboxylate-containing texaphyrin. Sessler and coworkers have intensively studied texaphyrin 
 
Figure 2.3. General structure of texaphyrin 
ligands. R can include a variety of different 
functional groups.  
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complexes with different functional groups including alcohol, ether, ethyleneglycol, amine, and 
chloro groups;
93–95 however, functional groups of complexes 2.2–2.7 have not been reported  
previously  with the texaphyrin motif. 
   
 The overall charge of complex 2.2 is +2, and it does not have acidic functional groups; 
thus, it was designed to use as a control if negative charge or acidic functional groups are crucial 
for myelin-specific interactions. Complexes 2.4–2.6 have sulfonic acid groups and charges of 0, 
–1, and –2, respectively, and they were designed to use to study the necessity of sulfonate groups  
and the effect of the number of sulfonate groups on interaction with myelin. Complexes 2.3 and 
2.7 have carboxylate groups with charges of 0 and –2, respectively, representing the carboxylate 
analogues of sulfonate texaphyrin complexes. All six of these complexes were designed to study 
with ex vivo mouse brain samples to investigate the important features for effective myelin-
specific binding. Syntheses of metal complexes 2.22.6 were achieved as outlined in  Scheme 
2.2.  
          
 
Figure 2.4.  Target texaphyrin complexes 
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The synthesis of complex 2.7 was not confirmed by any characterization technique—including 
mass spectrometry, NMR spectroscopy, and UV–vis spectroscopy—despite the employment of a 
variety of synthetic conditions (Table 2.1). Hence, the synthesis of complex 2.7 was not 
 
Scheme 2.2.  Synthetic route to Gd
III
-containing texaphyrin complexes 2.22.6. 
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achieved. However, this set back did not affect the studies of myelin binding because complexes 
2.22.6 contain all of the necessary variables to complete the planned studies.  
Table 2.1. Synthetic conditions attempted toward the synthesis of  complex 2.7     
Starting material Reaction type and 
 reaction conditions 
Observations  
 
 
metallation  
Gd(OAc)3·4H2O,  
triethylamine, methanol, 
air, reflux 
A precipitate formed from the 
reaction mixture. 
 UV–vis spectrum did not show 
the formation of metallated 
complex.  
 
 
 
 
Sapponification of esters  
1. LiOH, THF, H2O 
2. NaOH, MeOH, H2O 
3. NH4OH (aq) 
4. Me3SnOH, C2H4Cl2, 80 °C 
5. NaOSi(CH3)3, THF 
6. DOWEX  8×50W-100,  H2O, 
reflux 
 
Conditions 1 and 2 resulted in 
depletion of metal-complex-
specific absorptions at 474 and 
740 nm. The resulting residue 
was insoluble in water and other 
common organic solvents. With 
conditions 3–6 the metal-
complex-specific absorptions 
were present. However, they also 
produced an insoluble residue 
and the only identifiable peak in 
mass spectra was starting 
material. 
 
Oxidation of alcohols 
1. Pyridiniumdichlorochromate, 
dimethylformamide  
2. 2,2,6,6-tetramethylpiperidine-
1-oxyl, PhI(OAc)2, H2O, 
acetonitrile 
3. KMnO4, NaOH 
 
1.  Depletion  of metal-complex-
specific absorptions at 474 and 
740 nm 
2. Alcohols oxidized to 
aldehydes  
3. Depletion of metal complex 
specific absorption and 
appearance of a new peak in the 
300–400 nm regions.  
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Experimental procedures for Gd
III
-containing target-specific metal complexes. 
Commercially available chemicals were of reagent-grade purity or better and were used 
without purification unless otherwise noted. Water was purified using a PURELAB Ultra Mk2 
water purification system (ELGA). Compounds 2.1c,
90
 2.1f,
19
 2.2b,
96
 2.2c,
95
 2.3c,
94
 and 2.2f
95
 
were synthesized using previously published procedures. Compounds 2.3a and 2.3b were 
synthesized following a similar procedure to reference 97. Compound 2.2e was synthesized 
following the procedure in reference 98 with some modifications to purification. 
Analytical thin-layer chromatography (TLC) was carried out on ASTM TLC plates 
precoated with silica gel 60 F254 (250 μm layer thickness). Visualization of TLC was 
accomplished using a UV lamp followed by charring with potassium permanganate stain (3 g 
KMnO4, 20 g K2CO3, 5 mL 5% w/v aqueous NaOH, 300 mL H2O) or by charring with ceric 
ammonium molybdate stain (4 g cerium(IV) sulfate hydrate complex with sulfuric acid, 100 g 
ammonium molybdate tetrahydrate, 900 mL H2O, 100 mL concentrated H2SO4).  Flash 
chromatography was performed using silica gel 60, 230–400 mesh (EMD Chemicals) or 
aluminum oxide, activated, acidic, Brockmann I, standard grade, ~150 mesh, 58 Å (Sigma 
Aldrich).  Preparative reverse-phase chromatography was performed using RP-tC18 SPE Sep-
Pak columns (Waters) and a high-performance liquid chromatography (HPLC) system 
(Shimadzu) equipped with a C18 column (Restek International, Viva C18, 5 μm, 250 × 10.0 
mm). Analytical HPLC analyses were performed with a C18 column (Restek International, Viva 
C18, 5 μm, 250 ×4.6 mm). Both preparative and analytical HPLC used a binary gradient method 
(pump A: water, pump B: acetonitrile; 5% B for 5 min, 5–30% B over 1 min, 30% B for 10 min, 
30–95% B over 1 min, 95% B for 2 min) for complex 2.1, and (pump A: water, pump B: 
acetonitrile; 5% B for 5 min, 5–95% B over 7 min, 95% B for 1 min, 95–5% B over 1 min) for 
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complexes 2.2–2.6. The flow rates used for preparative and analytical columns were 5 and 1 
mL/min, respectively. Detection was carried out with a photodiode array detector and 
fluorescence detector (λex = 395 nm, and λem = 521 nm).  
 
1
H NMR spectra were obtained using a Varian Mercury 400 (400 MHz) spectrometer, 
Agilent 400 (400 MHz), Varian 500 (500 MHz), or  Agilent 600 (600 MHz) spectrometers, and 
13
C NMR spectra were obtained using a Varian Mercury 400 (101 MHz), Agilent 400 (101 
MHz), Varian 500 (126 MHz), or Agilent 600 (151 MHz) spectrometers. Chemical shifts are 
reported relative to residual solvent signals unless otherwise noted (CDCl3: 
1H: δ 7.27, 13C: δ 
77.16; dimethylsulfoxide-d6: 
1
H: 2.50, 
13
C: 39.52; D2O: 
1
H: 4.79, 
13
C: 49.00 for an internal 
standard of methanol-d4 or 39.52 for an internal standard of dimethyl sulfoxide-d6; CD3OD/D2O 
mixture, 
1
H: 4.79, 
13
C: 49.00). NMR data are assumed to be first order, and the apparent 
multiplicity is reported as “s” = singlet,  “d” = doublet, “dd” = doublet of doublets, “t” = triplet, 
“q” = quartet, “m” = multiplet, or “brs” = broad singlet. Italicized elements are those that are 
responsible for the chemical shifts. High-resolution electrospray ionization mass spectra 
(HRESIMS) were obtained on an electrospray time-of-flight high-resolution Waters Micromass 
LCT Premier XE mass spectrometer. UVvis spectra were obtained on Shimadzu UVmini-1240 
UVvis spectrophotometer. Data are reported as UV–vis (solvent) max, nm (ε). Abbreviations: 
max is the wavelength of maximum absorption in nanometers; ε is the molar absorption 
coefficient; and sh is the shoulder. Fluorescence spectra were obtained using a HORIBA Jobin 
Yvon Fluoromax-4 spectrofluorometer. 
  Sonication was performed using a FS60H sonicator (Fisher Scientific). Centrifugation 
was performed using a mini-centrifuge (05-090-100, Fisher Scientific) at 6600 rpm or 
Centrific™ Centrifuge at 7000 rpm (04-978-50, Fisher Scientific). Vortexing was done using a 
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vortex mixer (Fisher Scientific). Freeze drying was performed using a Freezone 2.5 freeze dryer 
(LABCONCO). Elemental analyses were performed by Midwest Microlab LLC, Indianapolis, 
Indiana, USA.  
 
β-amyloid-targeted metal complex 
tert-Butyl-2-(2-(4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-3-oxohepta-1,4,6-
trienyl)-2-methoxyphenoxy)acetamido)ethylcarbamate (2.1d): 
To a solution of commercially available curcumin, 2.1a, (205 mg, 0.557 mmol, 1 equiv) 
in anhydrous methanol (7 mL) at 50 °C was added a solution of sodium methoxide (0.81 mmol, 
0.54 M, 1.5 equiv) in anhydrous methanol (1.5 mL) dropwise over a period of 20 min under Ar. 
The resulting reaction mixture was stirred for 40 min at 50 °C under Ar. A mixture of amine 
linker 2.1c (323 mg, 1.36 mmol, 2.5 equiv) and KI (186 mg, 1.12 mmol, 2 equiv)  in anhydrous 
methanol (1 mL) was added to the reaction mixture dropwise over 15 min. Anhydrous toluene (3 
mL) was added, and the resulting reaction mixture was stirred at 80 °C under Ar for 22 h in the 
dark.  Volatiles were removed under reduced pressure, and the resulting solid was purified using 
silica gel column chromatography (stepwise gradient of 2:3→4:1→1:0 ethyl acetate/hexanes) to 
yield 2.1d (0.11 g, 34%) as an orange oil. 
1
H NMR (400 MHz, CDCl3, δ): 1.43 (s, CH3, 9H), 
3.18–3.58 (m, CH2, 4H), 3.95 (s, CH3, 6H), 4.57 (s, CH2, 2H), 4.87 (brs, NH, 1H), 5.83 (s, CH, 
1H), 5.96 (brs, OH, 1H), 6.49 (d, J = 15.98 Hz, CH, 1H), 6.52 (d, J = 15.58 Hz, CH, 1H), 6.80–
7.19 (m, ArH, 6H), 7.22 (brs, NH, 1H), 7.59 (d, J = 15.58 Hz, CH, 1H), 7.61 (d, J = 15.98 Hz, 
CH, 1H), 16.01 (brs, OH, 1H); 
13
C NMR (101 MHz, CDCl3, δ): 28.5 (CH3), 39.6 (CH2), 40.6 
(CH2), 56.1 (CH3), 56.2 (CH3), 69.2 (CH2), 79.8, 101.6 (CH), 109.8 (CH), 110.9 (CH), 114.9 
(CH), 115.1 (CH), 121.9 (CH), 122.2 (CH), 123.2 (CH), 123.3 (CH), 127.7, 130.3, 139.8 (CH), 
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141.1 (CH), 147.0, 148.2, 148.8, 149.9, 156.5, 169.1, 182.6, 184.2; TLC: Rf = 0.23 (4:1 
ethylacetate/hexanes); HRESIMS (m/z): [M + H]
+
calcd for C30H37N2O9, 569.2499; found, 
569.2504. 
Curcumin-conjugated Gd
III
DTPA complex (2.1): 
Compound 2.1d (34 mg, 0.060 mmol) was added to a solution of HCl (3 M) in ethyl 
acetate (2.5 mL), and the resulting mixture was stirred at ambient temperature for 30 min. 
Solvents were removed under reduced pressure, and the product was triturated with diethyl ether 
(2 × 3 mL) to obtain a brown solid (26 mg, 0.056 mmol, 1 equiv) that was dissolved in water 
(0.2 mL). To the resulting solution was added a solution of DIEA (39 µL, 0.22 mmol, 4 equiv) in 
acetonitrile (0.2 mL) dropwise over 5 min while stirring. At the end of the addition, water (0.2 
mL) was added to the reaction mixture followed by complex 2.1f (55 mg, 0.079 mmol, 1.4 
equiv) as a solid in 4 equal portions. Upon complete addition of 2.1f, water (1.1 mL) was added 
to the reaction mixture that was subsequently sonicated  (1 min). The reaction mixture was 
stirred in the dark at ambient temperature for 6.5 h then purified by reverse-phase 
chromatography using RP-tC18 SPE Sep-Pak (stepwise gradient of 3:7→1:1 acetonitrile/water) 
followed by HPLC. Volatiles were removed under reduced pressure, and the resulting residue 
was dissolved in water (1 mL) and freeze dried to obtain 2.1 (0.010 g, 16%) as a fluffy yellow 
powder. HRESIMS (m/z): [M]
2– 
calcd for C47H51N6O17SGd, 579.1129; found, 579.1102. HPLC 
chromatograms on page 115 in Appendix B. 
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Myelin-targeted metal complexes 
Benzyl 4-ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate (2.3a): 
 To a vigorously stirring suspension of diethylaminomalanoate hydrochloride salt (3.0 g, 
14 mmol, 1 equiv) in CH2Cl2 (30 mL) was added a saturated solution of NaHCO3 (22.5 mL) 
dropwise over 20 min, and stirring was continued for 20 min. The aqueous layer was decanted. 
The organic layer was dried over anhydrous MgSO4, filtered, and the solvent was removed under 
reduced pressure to yield 2.5 g (95%) of diethylaminomalanoate as a colorless liquid.  To 
refluxing glacial acetic acid (12 mL) was added a mixture of diethylaminomalanoate (2.0 g, 11 
mmol, 1 equiv) and 3-ethyl-2,4-pentanedione (1.5 g, 11 mmol, 1 equiv) dropwise over 30 min. 
The reaction mixture was heated at reflux for 3 h and poured into ice. The resulting precipitate 
was filtered and the solvent was removed under reduced pressure to yield 1.2 g (60%) of ethyl 4-
ethyl-3,5-dimethyl-1H-pyrrole-2-carboxylate as an off white crystalline solid. 
1
H NMR (400 
MHz, CDCl3, δ): 1.06 (t, J = 7.6 Hz, CH3, 3H),  1.35 (t, J = 7.2 Hz, CH3, 3H), 2.21 (s, CH3, 3H), 
2.29 (s, CH3, 3H), 2.39 (q, J = 7.6 Hz, CH2, 2H), 4.30 (q, J = 7.2 Hz, CH2, 2H), 8.70 (brs, NH, 
1H); 
13
C NMR (101 MHz, CDCl3, δ): 10.6 (CH3), 11.5 (CH3), 14.7 (CH3), 15.5 (CH3),  17.3 
(CH2), 59.7 (CH2), 116.8, 124.0, 126.9, 129.2, 161.9. 
 To a gradually heating (from ambient temperature to 200 °C over 2 h) solution of 4-ethyl-
3,5-dimethyl-1H-pyrrole-2-carboxylate (1.25 g, 6.41 mmol, 1 equiv) in benzyl alcohol (6 mL) 
was added a mixture of sodium (14.8 mg, 0.641 mmol, 0.1 equiv) dissolved in benzyl alcohol 
(1.2 mL) portionwise over 2 h. After the addition of sodium, the reaction mixture was stirred for 
5 min at 200 °C, and the hot solution was poured into a cooled mixture of  ethanol/water/glacial 
acetic acid (0 °C, 1:0.75:0.01, 14.1 mL). The resulting mixture was cooled at 0 °C for 20 min. 
The resulting precipitate was filtered, and washed with cold ethanol (0 °C, 2 mL). Solvent was 
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removed under reduced pressure to yield 1.18 g (72%) of 2.3a as a white fluffy solid. 
1
H NMR 
(400 MHz, CDCl3, δ): 1.05 (t, J = 7.6 Hz, CH3, 3H),  2.20 (s, CH3, 3H), 2.30 (s, CH3, 3H), 2.39 
(q, J = 7.6 Hz, CH2, 2H), 5.30 (s, CH2, 2H), 7.30–7.45 (m, CH, 5H), 8.54 (brs, NH, 1H); 
13
C 
NMR (101 MHz, CDCl3, δ): 10.7 (CH3), 11.5 (CH3), 15.5 (CH3), 17.3 (CH2),  65.5 (CH2), 124.2, 
128.1 (CH), 128.2 (CH), 128.7 (CH ), 129.5, 136.8. 
 
Benzyl 4-(3-bromopropyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (2.4a): 
Compound 2.2a (1.5 g, 4.7 mmol, 1 equiv) was cooled to 0 °C, and to it was added BH3-
THF (1 M, 24 mL, 24 mmol, 5 equiv) dropwise while stirring. The reaction mixture was allowed 
to warm to ambient temperature and stirred for 5 h. Excess BH3-THF was quenched with 
CH3OH (20 mL), and the solvent was removed under reduced pressure. The resulting residue 
was dissolved in CH2Cl2 and washed with HCl (0.5 M,  2 × 20 mL). The organic layer was dried 
with anhydrous K2CO3, and the solvent was removed under reduced pressure to yield 1.34 g 
(98%) of  reduced 2.2a as a white powder. 
1
H NMR (400 MHz, CDCl3, δ): 1.49 (brs, OH, 1H), 
1.64–1.86 (m, CH2, 2H), 2.20 (s, CH3, 3H), 2.30 (s, CH3, 3H), 2.47 (t, J = 7.4 Hz, CH2, 2H), 3.64 
(t, J = 5.6 Hz, CH2, 2H), 5.30 (s, CH2, 2H), 7.29–7.56 (m, CH, 5H), 8.79 (brs, NH, 1H); 
13
C 
NMR (101 MHz, CDCl3, δ): 10.8 (CH3), 11.6 (CH3), 20.3 (CH2), 33.6 (CH2),  62.5 (CH2), 65.6 
(CH2), 116.6, 121.5, 127.8, 128.1 (CH), 128.2 (CH), 128.6 (CH), 130.2, 136.7, 161.5; HRESIMS 
(m/z): [M + H]
+ 
calcd for C17H22NO3, 288.1600; found, 288.1641. 
To a solution of reduced 2.2a (0.90 g, 3.2 mmol, 1 equiv) in anhydrous CH2Cl2 was 
added CBr4 (1.6 g, 4.8 mmol, 1.5 equiv). The resulting mixture was cooled to 0 °C and stirred 
for 10 min under Ar in the dark. To this mixture was added PPh3 (1.3 g, 4.8 mmol, 1.5 equiv), 
and the mixture was stirred for 1.5 h at ambient temperature under Ar in the dark. Solvent was 
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removed under reduced pressure, and the resulting viscous oil was purified by silica gel 
chromatography (1:5 ethyl acetate/hexanes) to obtain 0.83 g (74%) of 2.4a as an off white 
powder. 
1
H NMR (400 MHz, CDCl3, δ): 1.92–2.12 (m, CH2, 2H), 2.23 (s, CH3, 3H), 2.32 (s, 
CH3, 3H), 2.55 (t, J = 8.0 Hz, CH2, 2H), 3.40 (t, J = 8.0 Hz, CH2, 2H), 5.32 (s, CH2, 2H), 7.31–
7.51 (m, CH, 5H), 8.99 (brs, NH, 1H); 
13
C NMR (101 MHz, CDCl3, δ): 10.9 (CH3), 11.6 (CH3), 
22.4 (CH2), 33.5 (CH2), 33.6 (CH2), 65.6 (CH2), 116.7, 120.4, 127.7, 128.1 (CH), 128.6 (CH), 
130.6, 136.7, 161.5; HRESIMS (m/z): [M + H]
+ 
calcd for C17H21NO2Br, 350.0756; found, 
350.0941; TLC: Rf = 0.44 (1:5 ethyl acetate/hexanes). 
 
Benzyl 5-(acetoxymethyl)-4-(3-ethyl)-3-methyl-1H-pyrrole-2-carboxylate (2.3b): 
To a stirring mixture of 2.3a (1.0 g, 3.9 mmol, 1 equiv) in glacial acetic acid (50 mL) was 
added acetic anhydride (15 mL) dropwise under Ar at ambient temperature. The reaction mixture 
was stirred for 15 min; Pb(OAc)4 (2.5 g, 5.6 mmol, 1.4 equiv) was added; and stirring was 
continued for 195 min.  The reaction mixture was poured onto ice, and the resulting precipitate 
was collected and washed with water (10 × 100 mL). The precipitate was dried under reduced 
pressure, dissolved in CHCl3 (4 mL), and precipitated using petroleum ether (150 mL) to yield  
1.0 g (82%) of 2.3b as a white fluffy powder. 
1
H NMR (400 MHz, CDCl3, δ): 1.11(t, J = 7.6 Hz, 
CH2, 3H), 2.07 (s, CH3, 3H), 2.32 (s, CH3, 3H), 2.49 (q, J = 7.6 Hz, CH2, 2H), 5.05 (s, CH2, 2H), 
5.33 (s, CH2, 2H), 7.31–7.48 (m, CH, 5H), 9.26 (brs, NH, 1H); 
13
C NMR (101 MHz, CDCl3, δ): 
10.5 (CH3), 16.0 (CH3), 17.2 (CH2), 21.0 (CH3), 57.0 (CH2), 65.8 (CH2), 119.0, 126.6, 127.0, 
127.1, 128.2 (CH), 128.6 (CH), 136.5, 161.4, 171.6. 
  
   
46 
 
Benzyl 5-(acetoxymethyl)-4-(3-bromopropyl)-3-methyl-1H-pyrrole-2-carboxylate (2.4b): 
To a stirring mixture of 2.4a (0.44 g, 1.2 mmol, 1 equiv) in glacial acetic acid (17 mL) 
was added acetic anhydride (5 mL) dropwise under Ar at ambient temperature. The reaction 
mixture was stirred for 15 min; Pb(OAc)4 (1.1 g, 2.5 mmol, 2 equiv) was added; and stirring was 
continued for 1 h.  The reaction mixture was poured on to ice, and the resulting precipitate was 
collected and washed with water (10 × 50 mL). The precipitate was dried under reduced 
pressure, dissolved in CH2Cl2 (2 mL), and filtered. The filtrate was precipitated using petroleum 
ether (100 mL) to yield  0.45 g (93%) of 2.4b as a white fluffy powder. 
1
H NMR (400 MHz, 
CDCl3, δ): 1.98–2.06 (m, CH2, 2H), 2.06 (s, CH3, 3H), 2.30 (s, CH3, 3H), 2.62 (t, J = 7.4 Hz, 
CH2, 2H), 3.39 (t, J = 6.4 Hz, CH2, 2H), 5.05 (s, CH2, 2H), 5.31 (s, CH2, 2H), 7.31–7.50 (m, CH, 
5H), 9.23 (brs, NH, 1H); 
13
C NMR (101 MHz, CDCl3, δ): 10.7 (CH3), 21.1 (CH3), 22.2 (CH2), 
33.3 (CH2), 33.8 (CH2), 57.0 (CH2), 65.9 (CH2), 119.3, 123.3, 126.8, 127.8 (CH), 128.3 (CH), 
128.7 (CH), 136.4, 161.2, 171.7; HRESIMS (m/z): [M + H]
+ 
calcd for C19H23NO4Br, 408.0811 
found, 408.0588. 
Benzyl-5,5’-(3,4-diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(4-(3-bromopropyl)-3-
methyl-1H-pyrrole-2-carboxylate) (2.4c): 
Compound 2.4b (0.39 g, 0.96 mmol, 2 equiv) and 3,4-diethylpyrrole (65 µL, 0.48 mmol, 
1 equiv) were suspended in CH3OH (27 mL) under Ar in the dark and heated at 60 °C for 1 h 
until a clear solution was obtained. To this clear solution was added p-toluene sulfonic acid (7.9 
mg, 0.041 mmol, 0.085 equiv) in CH3OH (1 mL). The resulting reaction mixture was stirred for 
1.5 h at 60 °C, at which point the volume was reduced by sparging N2 through the reaction 
mixture (5–10 min) until a precipitate started to form. Once precipitation started, N2 sparging 
was stopped, and reaction was stirred for 4 h at 60 °C. The reaction mixture was concentrated to 
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10 mL under reduced pressure and cooled to –20 °C for 2 h to promote precipitation. The 
precipitate was separated, washed with cold CH3OH (0 °C, 2 mL) and dried under reduced 
pressure to yield 0.24 g (60%) of 2.4b as a pink powder.  
1
H NMR (400 MHz, CDCl3, δ): 1.19 (t, 
J = 7.4 Hz, CH3, 6H), 1.84–2.03(m, CH2, 4H), 2.26 (s, CH3, 6H), 2.42–2.66 (m, CH2, 8H), 3.36 
(t, J = 6.2 Hz, CH2, 4H), 3.62 (brs, CH2, 4H), 4.35 (brs, CH2, 4H), 6.96–7.10 (m, CH, 4H), 7.24–
7.39 (m, CH, 6H), 8.85 (brs, NH, 1H), 11.33 (brs, NH, 2H); 
13
C NMR (101 MHz, CDCl3, δ): 
11.3 (CH3), 17.0 (CH3), 17.8 (CH2), 21.9 (CH2), 22.1(CH2), 33.3 (CH2), 33.6 (CH2), 65.2 (CH2), 
117.3, 118.8, 119.3, 122.0, 126.2 (CH), 126.6, 127.1 (CH), 127.9 (CH), 133.7, 136.5, 162.5; 
HRESIMS (m/z): [M + H]
+ 
calcd for C42H50N3O4Br2, 818.2168; found, 818.2140.   
 
Dimethyl-3,3’-(2,2-(3,4-diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(5-formyl-4-methyl-
1H-pyrrole-3,2-diyl))dipropanoate (2.2d): 
A mixture of tripyrrane 2.2c (0.38 g, 0.51 mmol, 1 equiv) and Pd/C (10%, 0.070 g, 0.067 
mmol) in anhydrous THF (12 mL) was degassed under reduced pressure and then saturated with 
hydrogen (1 atm), and the resulting reaction mixture was stirred for 6 h at ambient temperature 
under an atmosphere of hydrogen. The reaction mixture was filtered through celite, and the 
solvents were removed under reduced pressure to obtain deprotected 2.2c as a pink powder. To 
deprotected 2.2c (0.29 g, 0.51 mmol, 1 equiv) was added trifluoroacetic acid (0.90 mL, 13 mmol, 
25 equiv) dropwise under Ar at ambient temperature while stirring. Upon complete addition of 
trifluoroacetic acid, the resulting solution was stirred for 10 min. The reaction mixture was 
cooled to 20 °C, and  triethylorthoformate (0.96 mL, 5.7 mmol, 11 equiv) was added dropwise. 
The resulting reaction mixture was stirred at 20 °C for 10 min before allowing the reaction 
mixture to warm to ambient temperature. Water (3.0 mL) was added dropwise to the stirring 
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mixture immediately after the temperature warmed above 20 °C, and stirring at ambient 
temperature was continued for 15 min. A dark red precipitate was collected and washed with 
water (5 × 5 mL). The precipitate was suspended in a mixture of water/ethanol/ammonium 
hydroxide (1:2:1 v/v/v, 5.0 mL) and stirred at ambient temperature for 1 h. The resulting yellow 
precipitate was filtered and washed with water (3 × 3 mL) followed by cold ethanol (0 °C, 2.0 
mL).  The precipitate was dissolved in a methanol/water mixture (5:1, 3.6 mL), heated to 60 °C 
for 5 min, cooled to ambient temperature, and concentrated under reduced pressure. The 
resulting suspension was cooled at 20 °C for 4 h then filtered, and the precipitate was washed 
with water (4.0 mL). Solvents were removed under reduced pressure to yield 171 mg (63%) of 
2.2d as a light brown solid. 
1
H NMR (400 MHz, CDCl3, δ): 1.11 (t, J = 7.4 Hz, CH3, 6H), 2.21 
(s, CH3, 6H), 2.31 (t, J = 7.8 Hz, CH2, 4H), 2.45 (q, J = 7.4 Hz, CH2, 4H), 2.71 (t, J = 7.8 Hz, 
CH2, 4H), 3.64 (s, CH3, 6H), 3.87 (s, CH2, 4H), 9.09 (s, CH, 2H), 9.30 (s, NH, 1H), 10.52 (s, 
NH, 2H); 
13
C NMR (101 MHz, CDCl3 δ): 8.9 (CH3), 16.7 (CH3), 17.8 (CH2), 19.3 (CH2), 22.8 
(CH2), 34.5 (CH2), 51.7 (CH3), 120.7, 120.9, 121.8, 128.2, 133.0, 138.7, 173.6 (CH), 175.6; 
HRESIMS (m/z): [M + H]
+  
calcd for C30H40N3O6, 538.2917; found, 538.2917. 
 
5,5’-(3,4-Diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(4-ethyl-3-methyl-1H-pyrrole-2-
carbaldehyde) (2.3d): 
Compound 2.3d was synthesized according to the procedure in reference 94 with some 
modifications to the protocol. The modifications included addition and stirring of triflouroacetic 
acid at ambient temperature, addition and stirring of triethylorthoformate at 20 °C, and 
purification by precipitation with  methanol at 20 °C, instead of extraction to yield 73% of 2.3d 
as a light brown solid. 
1
H NMR (400 MHz, CDCl3, δ): 0.80–1.29 (m, CH3, 12H), 2.20 (s, CH3, 
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6H), 2.32–2.56 (m, CH2, 8H), 3.84 (s, CH2, 4H), 9.14 (s, CH, 2H), 9.39 (s, NH, 1H), 10.11 (s, 
NH, 2H); 
13
C NMR (101 MHz, CDCl3, δ): 8.8 (CH3), 15.1 (CH3), 16.5 (CH3), 16.9 (CH2), 17.7 
(CH2), 22.7 (CH2), 120.8, 121.5, 124.8, 128.2, 132.9, 138.0, 175.6 (CH); HRESIMS (m/z): [M + 
H]
+ 
calcd for C26H36N3O2, 422.2808; found, 422.2808. 
 
5,5’-(3,4-Diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(4-(3-bromopropyl)-3-methyl-1H-
pyrrole-2-carbaldehyde) (2.4d): 
A mixture of tripyrrane 2.4c (0.60 g, 0.73 mmol, 1 equiv) and Pd/C (10%, 0.10 g, 0.095 
mmol) in anhydrous THF (18 mL) was degassed under reduced pressure and saturated with 
hydrogen (1 atm), and the reaction mixture was stirred for 6 h at ambient temperature under an 
atmosphere of hydrogen. The reaction mixture was filtered through celite, and solvent was 
removed under reduced pressure to obtain deprotected 2.4c as a pink powder. To deprotected 
2.4c (0.46 g, 0.73 mmol, 1 equiv) was added trifluoroacetic acid (0.67 mL, 8.9 mmol, 12 equiv) 
dropwise under Ar at ambient temperature while stirring. Upon complete addition of 
trifluoroacetic acid, the resulting solution was stirred for 10 min. The reaction mixture was 
cooled at 20 °C, and  triethylorthoformate (0.79 mL, 4.8 mmol, 6.5 equiv) was added dropwise 
over 15 min. The resulting reaction mixture was stirred at 20 °C for 15 min; the cold bath was 
removed; and water (22 mL) was added dropwise without stirring immediately after the 
temperature warmed above 20 °C. The reaction mixture was left to stand for 30 min at ambient 
temperature, and a dark red precipitate was collected and washed with water (5 × 10 mL). The 
precipitate was suspended in ethanol (8.6 mL), and a mixture of ammonium hydroxide/water 
(1:3 v/v, 8.5 mL) was added. The reaction mixture was stirred at ambient temperature for 20 min. 
The resulting precipitate was separated and washed with water (5 × 20 mL) until washings were 
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neutral as measured by pH paper. The resulting solid was dissolved in CH2Cl2 (5 mL) and 
precipitated using CH3OH/water  (8:1, 45 mL). The resulting suspension was cooled to 20 °C 
for 24 h, filtered, and washed with water (5.0 mL). Solvents were removed under reduced 
pressure to yield 371 mg (84%) of 2.4d as a light brown solid.  
1
H NMR (400 MHz, CDCl3, δ): 
1.12 (t, J = 7.4 Hz, CH3, 6H), 1.82–1.96 (m, CH2, 4H), 2.20 (s, CH3, 6H), 2.46 (q, J = 7.4 Hz, 
CH2, 4H), 2.54 (t, J = 7.2 Hz, CH2, 4H), 3.31 (t, J = 6.4 Hz, CH2, 4H), 3.87 (brs, CH2, 4H), 9.07 
(s, CH, 2H), 9.26 (brs, NH, 1H), 10.74 (brs, NH, 2H); 
13
C NMR (101 MHz, CDCl3, δ): 9.2 
(CH3), 16.8 (CH3), 17.9 (CH2), 22.3 (CH2), 22.9 (CH2), 33.3 (CH2), 33.4 (CH2), 120.6, 121.2, 
121.8, 128.2, 133.3, 139.0, 175.5 (CH); HRESIMS (m/z): [M + H]
+ 
calcd for C28H38N3O2Br2, 
606.1331; found, 606.1338.   
Sodium 3,3’-(2,2’-(3,4-diethyl-1H-pyrrole-2,5-diyl)bis(methylene)bis(5-formyl-4-methyl-
1H-pyrrole-3,2-diyl))dipropane-1-sulfonate (2.5d): 
To a solution of 2.4d (0.20 g, 0.33 mmol, 1 equiv) in p-dioxane (12 mL) was added an 
aqueous solution of KI (0.14 g, 0.80 mmol, 2.5 equiv, 2.0 mL), and the resulting mixture was 
stirred for 30 min at 80 °C under Ar. To the resulting mixture was added an aqueous solution of 
Na2SO3 (0.24 g, 1.9 mmol, 6.0 equiv, 2.0 mL), and the mixture was stirred for 24 h under Ar at 
80 °C. Solvents were removed under reduced pressure, and the resulting residue was purified by 
reverse-phase chromatography using RP-tC18 SPE Sep-Pak (stepwise gradient of 1:0→7:3 
water/CH3OH). Volatiles were removed under reduced pressure, and the resulting residue was 
dissolved in water (2 mL) and freeze dried  to yield 0.16 g (76%) of 2.5d as a brown fluffy 
powder. 
1
H NMR (400 MHz, D2O, δ): 0.91 (t, J = 6.6 Hz, CH3, 6H), 1.61–1.74 (m, CH2, 4H), 
2.14 (s, CH3, 6H), 2.21–2.44 (m, CH2, 8H), 2.70 (t, J = 7.4 Hz, CH2, 4H), 3.80 (s, CH2, 4H), 9.06 
(s, CH, 2H); 
13
C NMR (101 MHz, D2O with dimethylsulfoxide-d6 internal standard δ): 9.8 
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(CH3), 17.4 (CH3), 18.6 (CH2), 23.3 (CH2), 24.3 (CH2), 26.4 (CH2), 52.1 (CH2),  122.7, 123.0, 
123.9, 129.0, 137.6, 141.8, 178.7 (CH); HRESIMS (m/z): [M + H]
+ 
calcd for C28H38N3O8S2, 
608.2100; found, 608.2116.   
 
3,3’-(1,2-Phenylenebis(oxy))dipropan-1-ol (2.2e): 
 Compound 2.2e was synthesized according to the procedure in reference 92 with some 
modifications to the protocol. The modification included purification using silica gel 
chromatography (stepwise gradient of 2:1→4:1, ethyl acetate/hexanes) to yield 80% of 2.2e as a 
white crystalline solid. 
1
H NMR (400 MHz, CDCl3, δ): 2.01–2.09 (m, CH2, 4H), 3.41 (brs, OH, 
2H), 3.82–3.87 (m, CH2, 4H), 4.16 (t, J = 5.8 Hz, CH2, 4H), 6.80–6.92 (m, CH, 4H); 
13
C NMR 
(101 MHz, CDCl3, δ): 32.2 (CH2), 61.3 (CH2), 68.0 (CH2), 113.4 (CH), 121.7 (CH), 148.8; 
HRESIMS (m/z): [M + H]
+ 
calcd for C12H18O4Na, 249.1103; found, 249.0938; TLC: Rf = 0.23 
(2:1 ethyl acetate/hexanes) 
 
3,3’-(1,2-Phenylenebis(oxy))dipropane-1-sulfonic acid (2.3e): 
Catechol  (0.72 g, 6.5 mmol, 1 equiv) was dissolved in a mixture of NaOH (0.65 g, 16 
mmol, 2.7 equiv) and ethanol (35 mL) under Ar, and the resulting mixture was heated at reflux 
until a clear solution was obtained. This mixture was added to propane sultone (1.8 g, 15 mmol, 
2.5 equiv) dropwise over 30 min under Ar. The reaction mixture was heated at reflux under Ar 
for 48 h. The reaction mixture was centrifuged while hot; liquid was decanted; and the resulting 
residue was washed with hot ethanol (60 °C, 3 × 25 mL).  The residue was dissolved in water (10 
mL) and sparged with gaseous HCl for 3 min. The acid-saturated solution was centrifuged, and 
the liquid was decanted and concentrated under reduced pressure. The concentrated liquid (3 
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mL) was precipitated using CH3OH (47 mL) and cooled to –20 °C. The solid residue was 
isolated, dissolved in water (5 mL), and purified by re-precipitation using CH3OH/diethyl ether 
(8:1 v/v, 45 mL) at –20 °C. The precipitate was separated and washed with diethyl ether (2 × 25 
mL). Volatiles were removed  under reduced pressure to obtain  0.82 g (37%) of 2.3e as an off 
white solid. 
1
H NMR (400 MHz, D2O, δ): 2.15–2.30 (m, CH2, 4H), 3.05–3.17 (m, CH2, 4H), 
4.12 (t, J = 6.4 Hz, CH2, 4H), 7.03 (s, CH, 4H); 
13
C NMR (101 MHz, D2O with internal standard 
of dimethylsulfoxide-d6, δ): 25.8 (CH2), 49.4 (CH2), 69.2 (CH2), 116.1 (CH), 123.7 (CH), 149.3; 
HRESIMS (m/z): [M –2H + Na]– calcd for C12H16O8S2Na, 375.0184;  found, 375.0247.   
 
Sodium 3-(2-methoxyphenoxy)propane-1-sulfonate (2.4e): 
2-Methoxyphenol (0.6 mL, 4 mmol, 1 equiv) was added to a mixture of NaOH (0.24 g, 
6.0 mmol, 1.5 equiv) and ethanol (15 mL) under Ar in the dark, and the resulting reaction 
mixture was heated at reflux until a homogeneous solution was obtained. This mixture was 
added to propane sultone (0.74 g, 6.0 mmol, 1.5 equiv) dropwise under Ar. The reaction mixture 
was heated at reflux under Ar for 20 h in the dark. The reaction mixture was centrifuged while 
hot; liquid was decanted; and the resulting residue was washed with hot ethanol (60 °C, 3 × 20 
mL).  The residue was dissolved in water (5 mL), precipitated using ethanol (40 mL), and cooled 
to –20 °C. The solid residue was isolated, and the volatiles were removed  under reduced 
pressure to obtain  0.83 g (84%) of 2.4e as an off white solid. 
1
H NMR (400 MHz, D2O, δ): 
2.14–2.27 (m, CH2, 2H), 3.04–3.15 (m, CH2, 2H), 3.84 (s,  CH3, 3H), 4.14 (t, J = 6.4 Hz, CH2, 
2H), 6.95–7.14 (m, CH, 4H); 13C NMR (101 MHz, D2O with an internal standard of 
dimethylsulfoxide-d6, δ): 25.6 (CH2), 49.2 (CH2), 56.9 (CH3), 68.6 (CH2), 113.6 (CH), 114.9 
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(CH), 122.9 (CH), 123.2 (CH), 148.5, 149.8.; HRESIMS (m/z): [M – H]– calcd for C10H13O5S, 
245.0484;  found, 245.0491. 
  
3,3’-(4,5-Dinitro-1,2-phenylene)bis(oxy)dipropane-1-sulfonic acid (2.3f): 
Sulfonic acid 2.3e (0.24 g, 0.68 mmol, 1 equiv) was dissolved in glacial acetic acid (3.9 
mL) and stirred for 15 min at 15 °C. To this mixture was added aqueous HNO3 (70%, 2.5 mL) 
dropwise over a period of 15 min while maintaining the temperature of the reaction mixture at 15 
°C. After the addition, the reaction mixture was warmed to ambient temperature and stirred for 
15 min. The reaction mixture was cooled to 15 °C, and fuming HNO3 (6.6 mL) was added 
dropwise over a period of 30 min while the temperature of the reaction mixture was held at 15 
°C.  After the addition, the reaction mixture was warmed to ambient temperature and stirred for 
64 h. The reaction mixture was concentrated under reduced pressure, and cold methanol (0 °C, 
2.0 mL) was added to form a precipitate. The precipitate was collected and dried under reduced 
pressure. Purification was performed using an RP-tC18 SPE Sep-Pak column (stepwise gradient 
of 1:9→1:4 CH3OH/water) to yield 151.6 mg (50%) of 2.3f as a yellow solid. 
1
H NMR (400 
MHz, D2O, δ): 2.22–2.37 (m, CH2, 4H), 3.11 (t, J = 7.4 Hz, CH2, 4H), 4.32 (t, J = 6.4 Hz, CH2, 
4H), 7.60 (s, CH, 2H); 
13
C NMR (101 MHz, D2O with internal standard of dimethylsulfoxide-d6, 
δ): 25.5 (CH2), 49.1 (CH2), 70.2 (CH2), 110.5 (CH), 137.6, 152.7; HRESIMS (m/z): [M – H]
–
 
calcd for C12H15N2O12S2, 443.0066; found, 443.0062. 
 
3-(2-Methoxy-4,5-dinitrophenoxy)propane-1-sulfonic acid (2.4f):  
Sulfonic acid 2.4e (0.80 g, 3.3 mmol, 1 equiv) was dissolved in glacial acetic acid (19 
mL) and stirred for 10 min at 15 °C. To this mixture was added aqueous HNO3 (70%, 12 mL) 
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dropwise over a period of 15 min while maintaining the temperature of the reaction mixture at 15 
°C. After the addition, the reaction mixture was warmed to ambient temperature and stirred for 
15 min. The reaction mixture was cooled to 15 °C, and fuming HNO3 (30 mL) was added 
dropwise over a period of 30 min while the temperature of the reaction mixture was held at 15 
°C.  After the addition, the reaction mixture was warmed to ambient temperature and stirred for 
46 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue 
was dissolved in water (0.5 mL), and precipitated using CH3OH/diethyl ether (1:1, 50 mL). The 
precipitate was collected and dried under reduced pressure to yield 0.80 g (72%) of 2.4f as a 
yellow solid. 
1
H NMR (400 MHz, D2O, δ): 2.22–2.33 (m, CH2, 2H), 3.09 (t, J = 7.6 Hz, CH2, 
2H), 3.96 (s, CH3, 3H),  4.24–4.32 (m, CH2, 2H), 7.51–7.56 (m, CH, 2H); 
13
C NMR (101 MHz, 
D2O with internal standard of dimethylsulfoxide-d6, δ): 25.3 (CH2), 48.8 (CH2), 58.3 (CH3), 69.9 
(CH2), 109.0 (CH), 109.7 (CH), 137.3, 152.2, 153.1; HRESIMS (m/z): [M – H]
– 
calcd for 
C10H11N2O9S, 335.0185; found, 335.0189. 
 
3,3’-(4,5-Diamino-1,2-phenylene)bis(oxy)dipropanoic acid hydrochloride salt (2.2g): 
A mixture of dinitro compound 2.2f (0.40 g, 1.2 mmol, 1 equiv), Pd/C (10%, 0.11 g, 0.10 
mmol), and ethanol (18 mL) was sonicated until 2.2f was dissolved. The resulting reaction 
mixture was degassed under reduced pressure, saturated with hydrogen (1 atm), and heated at 
reflux for 3 h under an atmosphere of hydrogen. Solvent was removed under reduced pressure; 
HCl (1 M, 10 mL) was added; and the resulting mixture was filtered through a 0.2 μm syringe 
filter. The filtrate was concentrated by removing solvent under reduced pressure to yield 367.3 
mg (88%) of 2.2g as a purple  hygroscopic solid. 
1
H NMR (400 MHz, D2O, δ): 2.70 (t, J = 6.0 
Hz,  CH2, 4H), 4.15 (t, J = 5.6 Hz, CH2, 4H), 6.96 (s, CH, 2H); 
13
C NMR (101 MHz, D2O with 
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internal standard of dimethylsulfoxide-d6, δ): 35.4 (CH2), 67.3 (CH2), 111.9 (CH), 120.8, 149.1, 
176.8; HRESIMS (m/z): [M − H]– calcd for C12H15N2O6, 283.0930; found, 283.0936. 
 
4,5-Diethyl-10,23-dimethyl-9,24-bis(methylpropanoate)-16,17-bis((methylpropanoate)oxy)-
13,20,25,26,27-pentaazapentacyclo-[20.2.1.1
3,6
.1
8,11,
.0
14,19
]heptacosa-
3,5,8,10,12,14,16,18,20,22,24-undecaene (2.2L):  
 To a mixture of tripyrrole 2.2d (0.12 g, 0.22 mmol, 1 equiv) in toluene/CH3OH (6:1, 140 
mL) under Ar was added a solution of diamine salt 2.2g (0.080 g, 0.22 mmol, 1 equiv) in 
CH3OH (4.0 mL). To the resulting reaction mixture was added HCl (11.6 M, 0.05 mL, 0.6 mmol, 
3 equiv), and the mixture was heated at 80 °C for 6 h under Ar. The reaction mixture was cooled 
to ambient temperature; K2CO3 (83 mg, 0.60 mmol, 3 equiv) was added; and stirring was 
continued for 30 min. The reaction mixture was filtered, and the filtrate was concentrated under 
reduced pressure. Solids were dissolved in methanol (4.0 mL) and cooled at 20 °C for 16 h to 
promote precipitation. The precipitate was collected, washed with diethyl ether (2.0 mL), and 
solvents were removed under reduced pressure to yield 76.4 mg (58%) of 2.2L as a bright red 
solid. 
1
H NMR (500 MHz, CDCl3, δ): 1.06 (t, J = 7.5 Hz, CH3, 6H), 2.27 (s, CH3, 6H), 2.38 (q, J 
= 7.5 Hz, CH2, 4H), 2.46 (t, J = 7.8 Hz, CH2, 4H), 2.70–2.91 (m, CH2, 8H), 3.71 (s, CH3, 6H), 
3.73 (s, CH3, 6H) 3.96 (dd, J = 15.5, 123.4 Hz, CH2, 4H), 4.25 (brs, CH2, 4H), 7.16 (s, CH, 2H), 
8.30 (s, CH, 2H), 11.07 (s, NH, 1H), 12.25 (s, NH, 2H); 
13
C NMR (126 MHz, CDCl3, δ): 9.8 
(CH3), 16.7 (CH3), 17.8 (CH2), 19.5 (CH2), 22.2 (CH2), 34.4 (CH2), 35.2 (CH2), 51.81 (CH3), 
51.82 (CH3), 65.2 (CH2), 102.6 (CH), 120.3, 120.4, 121.2, 125.3, 131.0, 133.5, 140.2, 141.6 
(CH), 148.0, 171.5, 173.2; HRESIMS (m/z): [M + H]
+ 
calcd for C44H56N5O10, 814.4027; found, 
814.4015; UVvis (30% CH3OH in water) max, nm (ε): 364 (48400). 
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4,5-Diethyl-10,23-dimethyl-9,24-bis(ethyl)-16,17-bis((propanesulfonicacid)oxy)-
13,20,25,26,27-pentaazapentacyclo-[20.2.1.1
3,6
.1
8,11,
.0
14,19
]heptacosa-
3,5,8,10,12,14,16,18,20,22,24-undecaene (2.4L): 
To a mixture of dinitrosulfonic acid 2.3f (52.8 mg, 0.118 mmol, 1 equiv) in 
water/CH3OH (1:2, 3.6 mL) was added Pd/C (10%, 26.8 mg, 0.0252 mmol). The resulting 
reaction mixture was degassed under reduced pressure and saturated with hydrogen (1 atm). The 
reaction mixture was heated at reflux for 40 min under an atmosphere of hydrogen until the 
solution became colorless. The resulting suspension was filtered through a 0.2 μm syringe filter 
into a mixture of 2.3d (50.4 mg, 0.118 mmol, 1 equiv)  in CH3OH/toluene/water (25:5:1, 62 mL) 
and HCl (11.6 M, 0.030 mL, 0.35 mmol, 3 equiv). The reaction mixture was stirred under Ar for 
6.5 h. Solvents were removed under reduced pressure, and the resulting residue was precipitated 
with CH3OH (5 mL) at –20 °C. The precipitate was isolated and purified by reverse-phase 
chromatography using an RP-tC18 SPE Sep-Pak (stepwise gradient of 1:1→1:4 water/CH3OH). 
Volatiles were removed under reduced pressure to yield 37 mg (41%) of 2.4L as a red powder. 
1
H NMR (600 MHz, dimethylsulfoxide-d6, δ): 1.01 (t, J = 7.5 Hz, CH3, 6H), 1.11 (t, J = 7.5 Hz, 
CH3, 6H), 2.01–2.07 (m, CH2, 4H), 2.30–2.37 (m, CH2, CH3, 10H), 2.50–2.53 (m, CH2, 4H), 
2.58 (t, J = 6.9 Hz, CH2, 4H), 3.95 (s, CH2, 4H), 4.26 (t, J = 6.9 Hz, CH2, 4H), 7.57 (s, CH, 2H), 
8.72 (s, CH, 2H), 10.43 (s, NH, 1H), 11.17 (s, NH, 2H);
 13
C NMR (151 MHz, dimethylsulfoxide-
d6, δ); 8.5 (CH3), 14.4 (CH3), 15.1 (CH3), 15.9 (CH2), 16.1 (CH2), 22.0 (CH2), 23.6 (CH2), 46.7 
(CH2), 66.6 (CH2), 101.3 (CH), 119.4, 120.0, 123.5, 125.1, 140.5 (CH), 147.1; HRESIMS (m/z) : 
[M – H]– calcd for C38H50N5O8S2, 768.3101; found, 768.3099; UVvis (30% CH3OH in water) 
max, nm (ε): 368 (38417).   
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Diethyl-10,23-dimethyl-9,24-bis(propanesulfonicacid)-16-((propanesulfonicacid)oxy)-17-
methoxy-13,20,25,26,27-pentaazapentacyclo-[20.2.1.1
3,6
.1
8,11,
.0
14,19
]heptacosa-
3,5,8,10,12,14,16,18,20,22,24-undecaene  (2.5L):  
To a mixture of dinitrosulfonic acid 2.4f (17 mg, 0.050 mmol, 1 equiv) in water/CH3OH 
(1:2, 1.8 mL) was added Pd/C (10%, 11 mg, 0.0010 mmol). The resulting reaction mixture was 
degassed under reduced pressure and saturated with hydrogen (1 atm). The reaction mixture was 
heated at reflux for 75 min under an atmosphere of hydrogen until the solution became colorless. 
The resulting suspension was filtered through a 0.2 μm syringe filter into a mixture of 2.5d in 
CH3OH/water (15:1, 32 mL) and HCl (11.6 M, 0.020 mL, 0.23 mmol, 4.6 equiv). The reaction 
mixture was stirred under Ar for 6 h. Solvents were removed under reduced pressure, and the 
resulting residue was purified by reverse-phase chromatography using an RP-tC18 SPE Sep-Pak 
(stepwise gradient of 1:0→7:3 water/CH3OH). Volatiles were removed under reduced pressure, 
and the resulting residue was dissolved in water (2 mL) and freeze dried to yield 24 mg (57%) of 
2.5L as a red fluffy powder. 
1
H NMR (600 MHz, CD3OD/D2O (5:2), δ): 0.87 (brs, CH3, 6H), 
1.90 (brs, CH2, 4H), 2.09 (brs, CH2, 2H), 2.20–2.36 (m, CH2, CH3, 10H), 2.65 (brs, CH2, 4H), 
2.81 (brs, CH2, 6H), 3.88 (s, CH3, 3H), 4.02 (brs, CH2, 4H), 4.18 (brs, CH2, 2H), 7.27–7.40 (m, 
CH, 2H), 8.43 (s, CH, 2H); 
13
C NMR (151 MHz, CD3OD/D2O (5:2), δ): 10.0 (CH3), 16.8 (CH3), 
18.2 (CH2), 23.3 (CH2), 24.2 (CH2), 25.1 (CH2), 26.2 (CH2), 49.8 (CH2), 51.7 (CH2), 57.4 (CH3), 
68.9 (CH2), 103.8 (CH), 104.6 (CH), 121.9, 123.5, 123.7, 124.5, 124.6, 126.1, 126.5, 127.0, 
127.2, 142.6 (CH), 142.9 (CH), 143.6, 149.3, 150.7, 152.5; HRESIMS (m/z): [M – H]–  calcd for 
C38H50N5O11S3, 848.2669; found, 848.2674; UVvis (30% CH3OH in water) max, nm (ε): 365 
(49529), 459 (sh, 15588).   
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4,5-Diethyl-10,23-dimethyl-9,24-bis(propanesulfonicacid)-16,17-
bis((propanesulfonicacid)oxy)-13,20,25,26,27-pentaazapentacyclo-
[20.2.1.1
3,6
.1
8,11,
.0
14,19
]heptacosa-3,5,8,10,12,14,16,18,20,22,24-undecaene  (2.6L): 
To a mixture of dinitrosulfonic acid 2.3f (23 mg, 0.050 mmol, 1 equiv) in water/CH3OH 
(1:2, 1.8 mL) was added Pd/C (10%, 11 mg, 0.0010 mmol). The resulting reaction mixture was 
degassed under reduced pressure and saturated with hydrogen (1 atm). The reaction mixture was 
heated at reflux for 35 min under an atmosphere of hydrogen until the solution became colorless. 
The resulting suspension was filtered through a 0.2 μm syringe filter into a mixture of 2.5d in 
CH3OH/water (15:1, 32 mL) and HCl (11.6 M, 0.020 mL, 0.23 mmol, 4.6 equiv). The reaction 
mixture was stirred under Ar for 6 h. Solvents were removed under reduced pressure, and the 
resulting residue was purified by reverse-phase chromatography using an RP-tC18 SPE Sep-Pak 
(stepwise gradient of 1:0→4:1 water/CH3OH). Volatiles were removed under reduced pressure, 
and the resulting residue was dissolved in water (2 mL) and freeze dried  to yield 25 mg (53%) 
of 2.6L as a red fluffy powder. 
1
H NMR (600 MHz, CD3OD/D2O (5:2), δ): 0.86 (t, J = 7.5 Hz, 
CH3, 6H), 1.86–1.94 (m, CH2, 4H), 2.05–2.11 (m, CH2, 4H), 2.34 (brs, CH2, CH3, 10H), 2.61–
2,68 (m, CH2, 4H), 2.78–2.84 (m, CH2, 8H), 4.04(s, CH2, 4H), 4.15–4.20 (m, CH2, 4H), 7.35 (s, 
CH, 2H), 8.45 (s, CH, 2H); 
13
C NMR (151 MHz, CD3OD/D2O (5:2), δ): 10.2 (CH3), 16.9 (CH3), 
18.2 (CH2), 23.3 (CH2), 24.4 (CH2), 25.1 (CH2), 26.3 (CH2), 49.8 (CH2), 51.8 (CH2), 69.0 (CH2), 
105.6 (CH),  121.7, 123.8, 124.4, 125.3, 127.7, 142.9 (CH), 144.7, 149.8, 153.9; HRESIMS 
(m/z): [M – H]– calcd for C40H54N5O14S4, 956.2550; found, 956.2527; UVvis (30% CH3OH in 
water) max, nm (ε): 363 (57217), 467 (sh, 16283).   
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Gd
III
 texaphyrin complex 2.2: 
To a stirring solution of texaphyrin 2.2L (0.060 g, 0.074 mmol, 1 equiv) in a mixture of 
CH2Cl2/CH3OH (1:4, 5 mL) was added triethylamine (99 µL, 0.74 mmol, 10 equiv). To the 
resulting solution was added Gd(OAc)3·4H2O (60 mg, 0.15 mmol, 2 equiv), and the reaction 
mixture was heated at 60 °C while sparging with air until the peak intensity ratio (742 nm/364 
nm) become constant (4.5 h). Solvents were removed under reduced pressure, and the resulting 
residue was purified using silica gel chromatography (stepwise gradient of 1:9→1:4 
CH3OH/CH2Cl2). Precipitation from CH3OH/CH2Cl2 (1:2, 0.5 mL) layered with CH3OH/diethyl 
ether (1:1, 3 mL) yielded 36.4 mg (45%) of 2.2 as a green solid. HRESIMS (m/z): [M + AcO

]
+
 
calcd for C46H53N5O12Gd, 1022.2917; found, 1022.2921; Anal. Calcd for 
C44H50N5O10GdCl3·CH3COOH·3H2O: C, 46.60; H, 5.02; N, 5.91. Found: C, 46.78; H, 4.64; N, 
6.10;  UVvis (30% CH3OH in water) max, nm (ε): 742 (32291), 470 (90902), 416 (sh, 52916); 
TLC: Rf = 0.24 (1:9 CH3OH/CH2Cl2). 
 
Gd
III
 texaphyrin complex 2.3: 
To a mixture of tripyrrole 2.3d (72 mg, 0.16 mmol, 1 equiv) in THF/toluene (5:1 v/v, 90 
mL) and HCl (11.6 M, 0.1 mL, 0.8 mmol, 5 equiv) was added a solution of diamine salt 2.2g 
(0.060 g, 0.16 mmol, 1 equiv) in water (1.0 mL), and the mixture was heated at 80 °C for 8.5 h 
under Ar. Solvents were removed under reduced pressure. To the resulting residue (0.10 g, 0.15 
mmol, 1 equiv) in CH3OH (8 mL) was added triethylamine (0.21 mL, 1.5 mmol, 10 equiv). To 
the resulting solution was added Gd(OAc3)3·4H2O (0.30 g, 0.75 mmol, 5 equiv), and the reaction 
mixture was heated at 60 °C while sparging with air until the peak intensity ratio (740 nm/370 
nm) became constant (20 h). Solvents were removed under reduced pressure. The resulting 
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residue was washed with CH3OH, dissolved in CH2Cl2, and purified by acidic alumina 
chromatography (stepwise gradient of 1:1:0→0:1:0.01 CH2Cl2/CH3OH/AcOH). Volatiles were 
removed under reduced pressure to yield 27 mg (22%) of 2.3 as a green powder. HRESIMS 
(m/z): [M – H]+ calcd for C38H41N5O6Gd, 821.2303; found, 821.3124 ; UVvis (30% CH3OH in 
water) max, nm (ε): 740 (30004), 474 (80403), 416 (sh, 48902). 
 
Gd
III
 texaphyrin complex 2.4: 
To a stirring solution of texaphyrin 2.4L (22 mg, 0.028 mmol, 1 equiv) in a mixture of 
CH2Cl2/CH3OH (1:2.5 v/v, 2.8 mL) was added triethylamine (40 µL, 0.28 mmol, 10 equiv). To 
the resulting solution was added Gd(OAc3)3·4H2O (46 mg, 0.11 mmol, 4 equiv), and the reaction 
mixture was heated at 60 °C while sparging with air until the peak intensity ratio (738 nm/368 
nm) became constant (4 h). Solvents were removed under reduced pressure, and purified using 
silica gel chromatography (stepwise gradient of 1:9→1:4 CH3OH/CH2Cl2). Purification by 
precipitation from CH3OH (5 mL) layered with diethyl ether (25 mL) yielded 9.7 mg (37%) of 
2.4 as a green solid. HRESIMS (m/z): [M + Na]
+ 
calcd for C38H44N5O8S2GdNa, 940.1755; found, 
940.1725; Anal. Calcd for C38H45N5O8GdS2Na2·3H2O: C, 44.69; H, 5.03; N, 6.86. Found: C, 
44.86; H, 5.03; N, 6.49; UVvis (30% CH3OH in water) max, nm (ε): 738 (27878), 473 (88060), 
416 (sh, 44727); TLC: Rf = 0.26 (1:4 CH3OH/CH2Cl2). 
 
Gd
III
 texaphyrin complex 2.5: 
To a stirring solution of texaphyrin 2.5L (50 mg, 0.059 mmol, 1 equiv) in CH3OH (6 mL) 
was added triethylamine (0.080 mL, 0.59 mmol, 10 equiv). To the resulting solution was added 
Gd(OAc3)3·4H2O (120 mg, 0.29 mmol, 5 equiv), and the reaction mixture was heated at 60 °C 
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while sparging with air until the peak intensity ratio (742 nm/365 nm) became constant (22 h). 
Solvents were removed under reduced pressure, and the resulting residue was purified by 
reverse-phase chromatography using an RP-tC18 SPE Sep-Pak (stepwise gradient of 1:0→7:3 
water/CH3OH). Volatiles were removed under reduced pressure. The resulting residue was 
dissolved in water (2 mL) and freeze dried to yield 30.2 mg (51%) of 2.5 as a green fluffy 
powder. HRESIMS (m/z): [M – H]+ calcd for C38H45N5O11S3Gd, 1001.1524; found, 1001.2540; 
Anal. Calcd for C38H43N5O11GdS3Na5·5H2O: C, 37.90; H, 4.44; N, 5.82. Found: C, 37.77; H, 
3.87; N, 5.82; UVvis (30% CH3OH in water) max, nm (ε): 742 (34571), 470 (93523), 416 (sh, 
46904). HPLC chromatogram on page 116 of Appendix B. 
 
Gd
III
 texaphyrin complex 2.6: 
To a stirring solution of texaphyrin 2.6L (0.048 g, 0.049 mmol, 1 equiv) in CH3OH (8 
mL) was added triethylamine (0.070 mL, 0.49 mmol, 10 equiv). To the resulting solution was 
added Gd(OAc3)3·4H2O (0.10 g, 0.25 mmol, 5 equiv), and the reaction mixture was heated at 60 
°C while sparging with air until the peak intensity ratio (743 nm/363 nm) became constant (6 h). 
Solvents were removed under reduced pressure, and the resulting residue was purified by 
reverse-phase chromatography using an RP-tC18 SPE Sep-Pak (stepwise gradient of 1:0→7:3 
water/CH3OH). Volatiles were removed under reduced pressure. The resulting residue was 
dissolved in water (2 mL) and freeze dried to yield 30.7 mg (55%) of 2.6 as a green fluffy 
powder. HRESIMS (m/z): [M – H]+ calcd for C40H49N5O14S4Gd, 1109.1411; found, 1109.2557; 
Anal. Calcd for C40H46N5O14GdS4Na8·8H2O: C, 33.50; H, 4.36; N, 4.88. Found: C, 33.55; H, 
3.84; N, 4.85; UVvis (30% CH3OH) max, nm (ε): 743 (30486), 472(82734), 416 (sh, 43146). 
HPLC chromatogram on page 117 of Appendix B. 
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CHAPTER 3. A multimodal, β-amyloid-targeted contrast agent 
Portions of this chapter are reproduced by permission of The Royal Society of Chemistry from 
Vithanarachchi, S. M.; Allen, M. J. Chem. Commun. 2013, 49, 4148–4150. 
http://pubs.rsc.org/en/content/articlepdf/2013/cc/c2cc36583a 
Introduction  
 β-Amyloid plaques are a diagnostic marker of Alzheimer’s disease, which is one of the 
most common neurodegenerative diseases in the world;
99 
hence, detection of β-amyloid plaques 
is important in the diagnosis of, in the monitoring of treatments for, and in research related to 
Alzheimer’s disease. The β-amyloid aggregates that comprise plaques are often detected using 
fluorescent dyes or β-amyloid-targeted radiolabels that interact with β-amyloid aggregates.100–105 
However, fluorescence microscopy has limited tissue penetration, and radiolabels for nuclear 
imaging use harmful ionizing radiation. Magnetic resonance imaging (MRI) is a non-invasive 
imaging technique with excellent tissue penetration and high spatial resolution (25–100 mm)6 
that has the potential to overcome the limitations of fluorescence microscopy and nuclear 
imaging with respect to the detection of β-amyloid aggregates. MRI has been used in several 
imaging studies of β-amyloid plaques.35,36,106–110 In these studies, both transverse relaxation time 
(T2)-weighted and longitudinal relaxation time (T1)-weighted imaging methods were 
reported.
35,36,106–109
 The T1-weighted methods are more desirable because T1-weighted imaging 
can distinguish plaques from hemorrhages and blood vessels unlike T2-weighted methods. 
Although T1-weighted imaging is desirable, it suffers from poor contrast enhancement of plaques 
leading to a widespread interest in the labeling of plaques with target-specific contrast agents. 
Examples of β-amyloid-targeting groups that have been reported include β-amyloid 
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peptides,
35,36,107 
monoclonal antibodies,
108
 and β-amyloid-binding dyes.109 Agents composed of 
conjugates of these targeting groups are capable of labeling β-amyloid plaques, but possible 
amyloidogenesis, toxicity, and the large size of these contrast agents limit their usefulness. These 
limitations reveal the need for new β-amyloid-targeted contrast agents with higher efficiency, 
smaller size, and non-amyloidogenic and non-toxic properties to make MRI a useful technique in 
β-amyloid imaging. 
 This chapter describes a β-amyloid-targeted contrast agent for MRI that is more efficient 
than current clinical contrast agents. To target β-amyloid aggregates, a non-toxic small molecule 
that can be traced with fluorescence microscopy was used; thus, this agent is multi-modal being 
detectable by both MRI and fluorescence microscopy. The multimodal contrast agent was 
synthesized using the conjugation strategy for target specific molecules by linking a clinically 
approved contrast agent to a target-specific moiety.
111
 For the target-specific moiety, curcumin, 
1,7-bis-(4-hydroxy-3-methoxy-phenyl)-1,6-heptadiene-3,5-dione, was chosen because it is non-
toxic, interacts with β-amyloid aggregates, is non amyloidogenic, and inhibits aggregate 
formation.
37,100–103
 Moreover, curcumin is fluorescent and has been used for imaging β-amyloid 
plaques with fluorescence microscopy.
37,100,101
 Curcumin conjugates are often synthesized via the 
total synthesis of curcumin derivatives
103,112,113 
or the direct reaction of linkers with 
commercially available curcumin.
113,114
 Total synthetic routes are tedious and limited to the 
synthesis of specific derivatives. Alternatively, the direct reaction of commercially available 
curcumin provides shorter synthetic routes and has been used to synthesize conjugates with 
reactive functional groups including alkenes, alcohols, esters, amides, cyanide, carboxylic acids, 
and azides.
113,114
  To facilitate conjugation to curcumin, an amine-functionalized linker was 
introduced at one of the phenolic sites of curcumin. That amine-functionalized curcumin is 
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expected to be a useful intermediate for other conjugations of curcumin because of the facile 
synthesis and resistance of amine-derived conjugates including amides, thioureas, ureas, and 
carbamates, to hydrolysis in enzyme-rich biological environments.
115
 The phenolic group was 
selected as a site of conjugation because conjugations to this position do not inhibit the targeting 
ability of curcumin.
103
 Furthermore, the amine group enabled facile reaction with an 
isothiocyanate derivative of Gd
III
diethylenetriaminepentaacetate (Gd
III
DTPA), which is a 
clinically approved contrast agent. 
In vitro studies of interaction between multimodal contrast agent and β-amyloid aggregates   
Conjugate 2.1 was synthesized via the direct reaction of commercially available curcumin 
with linker 2.1c to obtain amine linker containing curcumin 2.1d as described in Chapter 2 
(Scheme 2.1). The reactions were performed in the dark because of the photoinstability of 
curcumin.
117
 The amine group was deprotected with HCl and reacted with isothiocyanate-
containing Gd
III
DTPA, 2.1f, to obtain curcumin-conjugated contrast agent 2.1. After synthesis, 
the efficiency of conjugate 2.1 as a contrast agent for MRI was determined as described under 
experimental procedures. The longitudinal relaxivity (r1) of 2.1 is 13.63 ± 0.03 mM
–1 
s
–1
 
[phosphate buffered saline (PBS), pH 7.4, 1.4 T, and 37 °C]. This value is 4.1 times greater than 
that of clinically approved Gd
III
DTPA under the same conditions (3.30 ± 0.06 mM
–1 
s
–1
 ). The 
high relaxivity of 2.1 demonstrates that it is an efficient contrast agent. The efficiency is likely 
caused by a slowing of the molecular reorientation rate upon conjugation to curcumin and 
potential aggregation in solution.
20
 To measure the interaction of 2.1 with β-amyloid aggregates, 
the T1 of solutions containing complex 2.1 was measured in the presence and absence of β-
amyloid fibrils that were prepared as described in experimental procedures.  The formation of 
fibrils (diameters of 200–600 nm) was confirmed with dynamic light scattering and transmission 
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electron microscopy. Different stoichiometries (0, 0.5, 1, and 2 equiv relative to 2.1) of 
aggregated β-amyloid were incubated with complex 2.1, and T1 values were measured at a 
clinically relevant field strength (1.4 T) at 37 °C in PBS (pH = 7.4). As a non-binding control, T1 
measurements of β-amyloid aggregates at each concentration were measured in the presence of 
clinically approved Gd
III
DTPA, and all measurements were replicated with independently 
prepared samples. The T1 of samples containing conjugate 2.1 that were incubated with 1 or 2 
equiv of β-amyloid aggregates were shorter than the blank of 2.1 that did not contain β-amyloid 
aggregates (Student t test, 99% confidence interval). However, the Gd
III
DTPA control did not 
have different T1 values at any concentration of β-amyloid aggregates (Student t test, 99% 
confidence interval) with respect to Gd
III
DTPA in the absence of β-amyloid aggregates. To 
quantify the magnitude of the influence of the interaction of fibrils with 2.1 on relaxation rates, 
values of ∆1/T1 were calculated for samples containing conjugate 2.1, the Gd
III
DTPA control, 
and PBS [eq (3.1)]. In eq (3.1), ∆1/T1 is the change in 1/T1 due to the interaction with β-amyloid 
aggregates; (1/T1)n is the relaxation rate in the presence of n equiv of β-amyloid aggregates 
where n = 0, 0.5, 1, or 2; and (1/T1)0 is the relaxation rate in the absence of β-amyloid aggregates. 
                                                                                                                                (3.1)  
A plot of ∆1/T1 vs equiv of β-amyloid aggregates demonstrates that there is an increase in 
relaxation rate for 2.1 with increasing amounts of β-amyloid aggregates (Figure 3.1).                  
A 67 × 10
–3
 s
–1
 (9%) change in 1/T1 in the presence of 2 equiv of β-amyloid aggregates was 
observed compared to in the absence of aggregates. The controls of Gd
III
DTPA with β-amyloid 
aggregates and the β-amyloid aggregates alone did not show an increase in relaxation rate as a 
function of β-amyloid concentration. Values of T1 were expected to decrease upon the interaction 
of contrast agents to macromolecules, like fibrillar aggregates, due to the reduction in tumbling 
 
 
  
  
 
  
 
 
 
 
  
 
 
 
66 
 
rate based on Solomon–Bloembergen–Morgan theory.20,32,117 Hence, a decrease in T1 values in 
the presence of β-amyloid aggregates provides evidence of the interaction of conjugate 2.1 with 
β-amyloid aggregates.  
 
 
 
 
 
 
 
 
 
 
To explore the multimodal nature of complex 2.1, the effect of β-amyloid aggregates on 
the fluorescence emission of conjugate 2.1 was investigated. Emission spectra were acquired at 
the end of each T1 measurement (Figure 3.2), and the fluorescence emission maximum of 
conjugate 2.1 (516 nm) was blue shifted 9 nm in the presence of 2 equiv of β-amyloid 
aggregates. Furthermore, the fluorescence intensity of conjugate 2.1 increased by 43% in the 
presence of 2 equiv of β-amyloid aggregates relative to 2.1 in the absence of β-amyloid 
aggregates. Similar observations have been reported for β-amyloid-specific fluorescent dyes due 
to their interaction with β-amyloid aggregates,37,104,109,118 thus agreeing with the measurements in 
this thesis and providing further indication of the presence of an interaction of complex 2.1 with 
the β-amyloid aggregates. The changes in emission wavelength and intensity make conjugate 2.1 
 
Figure 3.1. Plot showing the change in relaxation rate (∆1/T1) as a function of 
the amount of β-amyloid (βA) aggregates in PBS. The relaxation rate of 2.1 
increases in the presence of βA, and the rate of the control samples do not: 2.1 
+ βA (□); GdIIIDTPA + βA (○); and βA (◊). Error bars represent standard error 
of the mean. 
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a multimodal imaging agent for β-amyloid plaques. Importantly, these probes allow for 
validation of results using orthogonal modalities: The multimodal nature of conjugate 2.1 
enables the validation of MRI results with fluorescence studies.  
 
 
 
 
 
 
 
 
 
 
Experimental procedures 
Commercially available chemicals were of reagent-grade purity or better and were used 
without purification unless otherwise noted. β-Amyloid peptide (1–42) was obtained from 
American Peptide Company Inc. Gd
III
diethylenetriaminepentaacetate (Gd
III
DTPA) was obtained 
as a 0.5 M aqueous solution  from Bayer HealthCare Pharmaceutical Inc. Water was purified 
using a PURELAB Ultra Mk2 water purification system (ELGA). Phosphate buffered saline 
(PBS) (1×, 11.9 mM phosphate, 137 mM NaCl, and 2.7 mM KCl, pH = 7.4) was used for 
amyloid fibril formation and relaxation time measurements. 
Dynamic light scattering measurements were obtained on a Zetasizer nanoparticle 
analyzer equipped with 633 nm helium–neon laser (NanoZS, Malvern Instruments Ltd.). 
 
Figure 3.2. Emission spectra (λex = 385 nm) of 2.1 and Gd
III
DTPA incubated 
with β-amyloid aggregates (βA) in PBS: 2 equiv βA + 2.1 (∙∙      ); 1 equiv. βA + 
2.1 (            ); 0.5 equiv βA + 2.1 (∙  ); 2.1 (---), 2 equiv βA + GdIIIDTPA (∙∙∙); and 
βA (─).The maximum emission of 2.1 undergoes a 9 nm blue shift and 43% 
increase in intensity upon interaction with 2 equiv of βA. 
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Transmission electron microscopy (TEM) was performed on a JEOL-2010 FasTEM 
Transmission Electron Microscope.  
Relaxation time (T1) measurements were obtained on a Bruker mq60 minispec NMR 
spectrometer at 60 MHz and 37 °C. Fluorescence spectra were obtained using a HORIBA Jobin 
Yvon Fluoromax-4 spectrofluorometer.  Sonication was performed using a FS60H sonicator 
(Fisher Scientific). Centrifugation was performed using a mini-centrifuge (05-090-100, Fisher 
Scientific) at 6600 rpm. Vortexing was done using a vortex mixer (Fisher Scientific). Spin 
filtration of amyloid protein was performed using SpinX 8161 (Costar) spin filters (0.22 µm).  
Rotating of β-amyloid samples was done using a Thermo Labquake Tube Shaker/Rotator. 
Inductively coupled plasma mass spectrometry (ICP–MS) analyses were performed by Columbia 
Analytical Services Inc, Tucson, Arizona, USA. 
 
Relaxivity measurements of 2.1 and Gd
III
DTPA 
Longitudinal relaxation times (T1) were measured using a standard recovery method with 
a Bruker Minispec mq 60 at 1.4 T and 37 °C in PBS. The slope of a plot of 1/T1 vs concentration 
of Gd
III
 was used to obtain relaxivity. Measurements were repeated 3 times with independently 
prepared samples, and Gd concentrations were determined by ICP–MS. T1 measurements of 
complex 2.1 are given in the Tables 3.1–3.3 for six different concentrations of GdIII (0–0.63 
mM). Linear plots obtained by plotting 1/T1 vs concentration for each trial are shown in Figures 
3.3–3.5. T1 measurements of Gd
III
DTPA are given in the Tables 3.4–3.6 for four different 
concentrations of Gd
III
 (0–1 mM). Linear plots obtained by plotting 1/T1 vs concentration for 
each trial are shown in Figures 3.6–3.8.  
 
69 
 
y = 13.58x + 0.07 
R² = 0.998 
0 
10 
0 0.7 
1
/T
1
 (
s–
1
) 
GdIII concentration (mM) 
Table 3.1 Relaxivity measurements of 2.1  Table 3.2 Relaxivity measurements of 2.1          
(trial 1).      (trial 2). 
Concentration (mM) T1 (s) 1/T1 (s
–1
) 
0.63 0.1137 8.80 
0.32 0.2380 4.20 
0.16 0.4959 2.02 
0.08 0.8838 1.13 
0.04 1.5010 0.67 
0.00 3.8600 0.26 
 
Table 3.3 Relaxivity measurements of 2.1 (trial 3). 
Concentration (mM) T1 (s) 1/T1 (s
–1
) 
0.63 0.1135 8.81 
0.32 0.2450 4.08 
0.16 0.4915 2.03 
0.08 0.8898 1.12 
0.00 3.8650 0.26 
      
  
 
 
 
 
Figure 3.3. Relaxivity plot of complex 2.1     Figure 3.4. Relaxivity plot of complex 2.1 
(trial 1).       (trial 2). 
 
 
 
 
 
 
 
Concentration (mM) T1 (s) 1/T1 (s
–1
) 
0.63 0.1141 8.76 
0.32 0.2350 4.26 
0.16 0.4902 2.04 
0.08 0.8915 1.12 
0.04 1.4350 0.70 
0.00 3.8460 0.26 
y = 13.63x + 0.06 
R² = 0.997 
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Figure 3.5. Relaxivity plot of complex 2.1 (trial 3).     
 
 
Table 3.4 Relaxivity measurements of  Table 3.5 Relaxivity measurements of  
Gd
III
DTPA (trial 1).  Gd
III
DTPA (trial 2). 
    
Concentration(mM) T1 (s) 1/T1 (s
–1
) 
1.00 0.2846 3.51 
0.50 0.5315 1.88 
0.25 0.9055 1.10 
0.00 3.8500 0.26 
 
Table 3.6 Relaxivity measurements of Gd
III
DTPA (trial 3). 
Concentration(mM) T1 (s) 1/T1 (s
–1
) 
1.00 0.2726 3.67 
0.50 0.5373 1.86 
0.25 0.9344 1.07 
0.00 3.8470 0.26 
           
 
 
 
 
 
 
Figure 3.6. Relaxivity plot of Gd
III
DTPA  Figure 3.7. Relaxivity plot of Gd
III
DTPA 
(trial 1).    (trial 2). 
Concentration(mM) T1 (s) 1/T1 (s
–1
) 
1.00 0.2865 3.49 
0.50 0.5384 1.86 
0.25 0.9366 1.07 
0.00 3.8460 0.26 
y = 13.67x + 0.01 
R² = 0.995 
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Figure 3.8. Relaxivity plot of Gd
III
DTPA (trial 3).  
 
Preparation of β-amyloid fibrils 
β-Amyloid peptide (1–42) (1 mg, 0.2 µmol)  was dissolved in PBS (1 mL) and stirred gently 
(350 rpm) at 37 ºC for 20 h to obtain a 0.2 mM stock solution of β-amyloid fibrils following 
published procedures.
100,104,119
  
Transmission electron microscopy (TEM) studies 
Aggregated β-amyloid peptide was centrifuged (0.2 mM, 100 µL), and the resulting sediment 
was suspended in water (20 µL) and mixed by vortexing. Aggregated protein solution (5 µL) was 
applied to a TEM substrate grid (200-mesh copper grid coated with Formvar/carbon film) and 
incubated for 10 min. Excess solution was removed with a filter paper. Phosphotungstic acid (1% 
(w/v), 3 µL) was applied to the grid containing protein. After incubation for 3 min, excess stain 
was washed with water (20–40 µL), and excess water was removed with a filter paper. The 
resulting sample was air dried for 3 h. TEM was performed at 100 kV (60,000×).  The TEM 
image (Figure 3.9) of aggregated fibrils is similar to the appearance of other reported TEM 
images of aggregated fibrils.
100,119
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Figure 3.9. TEM image of β-amyloid aggregates. 
 
Dynamic light scattering (DLS) studies of fibril formation 
 A 100 µL aliquot was taken from the β-amyloid stock while stirring and filtered through 
a 0.22 µm spin filter to remove large aggregates. The filtered solution was transferred to a 
disposable microcuvette (40 µL) and measured for size distribution by collecting data at a 173º 
measurement angle on a Zetasizer NanoZS instrument at 24.9 ºC (dispersant refractive index = 
1.332, and viscosity = 0.9128 cP). Size distribution data obtained from DLS based on intensity 
(Figure 3.10) provide evidence for the presence of fibril aggregates with diameters of 200–600 
nm that are comparable to the sizes of aggregates reported in other studies.
120
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Figure 3.10. Dynamic light scattering distribution data of β-amyloid aggregates (intensity 
distribution). 
 
Binding studies between conjugate 2.1 and amyloid fibrils 
Aliquots (0, 25, 50, and 100 µL) were taken from the stirring stock solution of β-amyloid 
aggregates and mixed with conjugate 2.1 (0.1 mM, 100 µL). The total volume of each sample 
was brought to 200 µL with PBS. Samples were vortexed (~5 s) and incubated at ambient 
temperature with rotation for 3 h.  β-Amyloid (0, 25, 50, and 100 µL) was mixed with PBS to a 
total volume of 200 µL, vortexed (~5 s), incubated with rotation for 3 h, and used as the  control. 
Gd
III
DTPA (0.1 mM, 100 µL) was used as the non-specific control, and samples with Gd
III
DTPA 
were prepared following the same procedure as for  conjugate 2.1. At the end of the incubation 
T1 relaxation times were measured for each sample (Table 3.7). Measurements were triplicated 
with independently prepared samples for complex 2.1 and measurements were duplicated for 
control samples. Fluorescence emission of samples was measured at the end of the relaxation 
time measurement. Samples were excited at 385 nm with a slit width of ±10 nm.   
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Table 3.7 β-Amyloid (βA) binding T1 measurements 
  
T1 (ms) at the following ratios of 
complex to βA* 
Sample (1:2) (1:1) (1:0.5) (1:0) 
2.1/βA (trial 1) 1267 1302 1339 1388 
2.1/βA (trial 2) 1265 1298 1395 1375 
2.1/βA (trial 3) 1262 1321 1328 1380 
 
    
GdDTPA/βA (trial 1) 2225 2243 2247 2253 
GdDTPA/βA (trial 2) 2232 2247 2243 2253 
 
    
βA control (trial 1) 3826 3822 3835 3865 
βA control (trial 2) 3815 3850 3830 3860 
*The concentration of βA in the βA control trials is the same as in the                                                         
samples containing 2.1 and GdDTPA at the same ratios. 
 
Conclusion  
An efficient, small molecular probe for β-amyloid aggregates from non-toxic curcumin 
and a derivative of a clinically approved contrast agent for MRI was synthesized. In vitro studies 
demonstrate that curcumin-conjugated contrast agent 2.1 interacts with β-amyloid aggregates 
resulting in a shortening of T1 and change in the wavelength and intensity of fluorescence 
emission. While future studies related to imaging and pharmacokinetic delivery are necessary to 
evaluate the utility of this work in vivo, the multimodal nature of imaging agent 2.1 is important 
for Alzheimer’s disease related research. In addition, we expect that the facile synthesis of the 
curcumin-amine linker will be a powerful tool for the synthesis of other curcumin conjugates that 
are stable in biological environments. 
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CHAPTER 4.  A myelin-specific, multimodal imaging agent for magnetic resonance, 
optical, and mass spectrometric imaging. 
Introduction  
The ability to view changes in the brain and peripheral nervous system is of great 
importance to the study of neurodegenerative diseases and aging,
121–124
 and among the  
components of the nervous system, myelin is a critical target for understanding neuronal 
anatomy and function.
125–127
 Myelin is a characteristic lipid-protein membrane in the nervous 
system that aids with the proper conduction of nerve impulse. Consequently, nerve cell 
deterioration caused by inherited or acquired neuropathologies and brain injuries often changes 
myelinated nerve structures.
125
 Hence, effective monitoring of the morphology of myelinated 
regions of the brain is important in the study of neurodegenerative diseases and therapies for 
these diseases.  
Histology using optical microscopy with chromophoric or fluorophoric stains was the 
primary method of imaging myelin until recently.
126,127
 Advancements in imaging technologies 
have permitted the use of other modalities for imaging myelin including positron emission 
tomography (PET) and magnetic resonance imaging (MRI). Although several PET tracers that 
target myelin have been reported,
122,128,129
 the use of PET for imaging myelinated structures in 
brain is limited because of its low (1–2 mm) resolution.6,122 Currently, the most promising non-
optical imaging method for myelin is MRI.
38,39,122,123,125
 The ability to acquire whole brain 
images using MRI with high resolution (25–100 µm)6  is important for in vivo imaging and ex 
vivo pre-clinical research. Various nonconventional and indirect MRI techniques have been 
investigated for imaging myelin including magnetization transfer, diffusion tensor imaging, T2 
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relaxometry, and ultrashort echo time MRI.
123,125
 But, the specificity of these methods for myelin 
is not ideal, and these methods struggle to distinguish changes in myelination from hemorrhages, 
iron deposits, and changes in the water content of tissue. 
 Myelin-specific contrast agents provide a way to augment the lack of specificity in 
myelin imaging; however, the three myelin-specific contrast agents for MRI that have been 
reported are limited by low relaxivity values.
38,39,81,130
  Myelin-specific Gd
III
-containing small 
molecules were reported that are similar in efficiency (5.1 mM–
1
 s–
1
) to nonspecific clinically 
approved contrast agents.
38,39,130
 These contrast agents were able to highlight myelination in MRI 
via T1 maps; however,  the images acquired with these agents demonstrate the need for contrast 
agents with higher relaxivities to produce images of myelinated structures with increased signal 
to noise ratios.
38,39,130
 Further, the Cu
II
-containing myelin-specific histology stain Luxol fast blue 
MBS (LFB MBS) was reported for imaging of myelinated brains with magnetic resonance 
spectroscopy.
81
 However, LFB MBS did not produce appreciable contrast because of the 
extremely low efficiency (0.09 mM–
1
 s–
1
) of the complex as a contrast agent for MRI.
81
 
Investigation of efficient myelin-specific agents for contrast-enhanced MRI is crucial for 
effective visualization of changes in brain tissues.  
Sensitive measurements of changes in tissue structure require high precision and 
accuracy, and one way to ensure the reliability of findings is with verification using orthogonal 
imaging techniques. Furthermore, the ability to combine techniques that produce high resolution 
structural images with techniques that yield chemical information enables the extraction of 
multiple types of information from a single tissue sample. Multimodal myelin-specific imaging 
agents would meet this need by allowing effective visualization of the distribution of myelin and 
the chemical composition of the agent. In this research, a new multimodal myelin-specific 
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contrast agents that are more efficient than clinically approved contrast agents for MRI and that 
can be used with light and near-IR fluorescence microscopies and mass spectrometric imaging 
were reported. We also report the imaging of myelinated structures in ex vivo samples using our 
new agents. 
Materials and Methods 
A detailed description of the synthesis and characterization of Gd
III
-containing texaphyrins 2.2–
2.6  is described in the Chapter 2. 
Animals. Animal care and use were in accordance with the National Institutes of Health Animal 
Care Guidelines and approved by the Wayne State University Institutional Animal Care and Use 
Committee. Intact brain tissue used for the section- and en bloc-staining techniques were 
obtained from euthanized C57Bl/6 mice that were bred in-house.
131
 Prior to euthanizing, all 
efforts were made to minimize suffering. The approval from Institutional Animal Care and 
Approval Committee to handle  mice in Prof. Conti Alana’s lab is included in Appendix C.  
Stain Preparation. Texaphyrin stain 2.2: To a mixture of ethanol (95%, 2 mL) and acetic acid 
(10%, 100 µL) was added texaphyrin 2.2 (4.4 mg, 0.0045 mmol, 1 equiv). The reaction mixture 
was heated at 60 °C for 18 h, cooled to ambient temperature, and filtered through a 0.2 µm filter 
to obtain stain 2.2 as a dark green solution. The stain solution was stored at 4 °C. The 
concentration of the stain solution was determined by ICP–OES.   
Texaphyrin stain 2.3: To a mixture of ethanol (100%, 2 mL) and acetic acid (10%, 100 µL) was 
added texaphyrin 2.3 (4.0 mg, 0.0048 mmol, 1 equiv) followed by ditolylguanidine (4.7 mg, 
0.019 mmol, 4 equiv) dissolved in acetic acid (1 M, 19 µL, 4 equiv). The reaction mixture was 
filtered through a 0.2 µm filter and heated at 60 °C for 18 h. The solution was cooled to ambient 
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temperature, and filtered through a 0.2 µm filter to obtain stain 2.3 as a dark green solution. The 
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.   
 
Texaphyrin stain 2.4: To a mixture of CH3OH/water (3:2 v/v, 1 mL) was added texaphyrin 2.4 
(4.2 mg, 0.0045 mmol, 1 equiv) followed by ditolylguanidine (4.4 mg, 0.018 mmol, 4 equiv) 
dissolved in acetic acid (1 M, 18 µL, 4 equiv). The reaction mixture was heated at 60 °C for 6 h. 
The solution was cooled to ambient temperature, and the solvent was removed under reduced 
pressure. The residue was dissolved in a mixture of ethanol (95%, 2 mL) and acetic acid (10%, 
100 µL), and the solution was heated at 60 °C for 14 h. The solution was cooled to ambient 
temperature and filtered through a 0.2 µm filter to obtain stain 2.4 as a dark green solution. The 
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.   
 
Texaphyrin stain 2.5: To a mixture of CH3OH/water (1:1 v/v, 1 mL) was added texaphyrin 2.5 
(4.1 mg, 0.0041 mmol, 1 equiv) followed by ditolylguanidine (6.0 mg, 0.025 mmol, 6 equiv) 
dissolved in acetic acid (1 M, 25 µL, 6 equiv). The reaction mixture was heated at 60 °C for 6 h. 
The solution was cooled to ambient temperature, and the solvent was removed under reduced 
pressure. The residue was dissolved in a mixture of ethanol (95%, 2 mL) and acetic acid (10%, 
100 µL), and the solution was heated at 60 °C for 14 h. The solution was cooled to ambient 
temperature and filtered through a 0.2 µm filter to obtain stain 2.5 as a dark green solution. The 
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.  
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Texaphyrin stain 2.6: To a mixture of CH3OH/water (1:2 v/v, 1 mL) was added texaphyrin 2.6 
(4.2 mg, 0.0038 mmol, 1 equiv) followed by ditolylguanidine (8.0 mg, 0.033 mmol, 8 equiv) 
dissolved in acetic acid (1 M, 33 µL, 8 equiv). The reaction mixture was heated at 60 °C for 6 h. 
The solution was cooled to ambient temperature, and the solvent was removed under reduced 
pressure. The residue was dissolved in a mixture of ethanol (95%, 2 mL) and acetic acid (10%, 
100 µL), and the solution was heated at 60 °C for 14 h. The solution was cooled to ambient 
temperature and filtered through a 0.2 µm filter to obtain stain 2.6 as a dark green solution. The 
stain solution was stored at 4 °C. The concentration of the stain solution was determined by ICP–
OES.   
  
Tissue Staining. Tissue Preparation. Formaldehyde (37% wt/v), Li2CO3, ethanol (200 proof), 
and agarose were purchased from Sigma Aldrich, Acros Organics, Decon Laboratories. Inc., and 
OmniPur, respectively. Tissues were acquired within 5 min of animal sacrifice and placed in a 
beaker of 3.7% (wt/v) aqueous formalin solution. Fixed tissue was stored at 4 °C in formalin. 
Prior to staining, fixed tissues were removed from formalin storage and rinsed with purified 
water (~10 mL) to remove formalin. 
Section-Staining Procedure. Tissue sections (200 µm thick) were obtained from fixed intact 
tissues using a vibrotome 3000 (MyNeuroLab). For each stain, three tissue sections were stained 
that provided observation of a diverse assortment of brain regions: 0.50 to 1.54, 0.14 to –0.58, 
and –1.58 to –2.18 mm from Bregma.132 Each tissue sample was incubated in  staining solution 
(2–0.8 mM, 0.2 mL) for 5 h at 54 °C. Tissue sections were removed from the staining solution 
and rinsed by swirling with ethanol (95%, 1 mL, 1 min) followed by water (1 mL, 1 min).  
Tissue stained with texaphyrin 2.2 were differentiated with a solution of Li2CO3 (4.5 mM) in 
ethanol (65%, 4 mL) for 30 min, three concentrations of ethanol (100, 95, and 70%, 4 mL each) 
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for 45 min each, and water (4 mL) for 5 min. All differentiations and rinsings were performed on 
a rotator (Thermo Labquake Tube Shaker/Rotator). Tissues stained with texaphyrins 2.3–2.6 
were differentiated with a solution of Li2CO3 (4.5 mM) in ethanol (65%, 4 mL) for 1–2 h, rinsed 
with ethanol (95%, 4 mL, 1 min), and hydrated in water (4 mL, 5 min for complexes 2.3 and 2.4, 
1 min for complexes 2.5 and 2.6). At the end of the differentiation and hydration, each tissue 
section was mounted on a microscope slide for imaging.  
En bloc-Staining Procedure. Intact mouse brains were incubated in solutions of texaphyrin 2.4 
(0.8 mM, 1.8 mL) for 24 h at 54 °C. At the end of the incubation, the brains were rinsed with 
ethanol (95%, 25 mL, 1 min) then water (25 mL, 1min). The brain tissue was pat dried with 
tissue paper, and an incision was made using a scalpel along the midline on the dorsal face of the 
intact brain, such that the incision reached the dorsal third ventricle. Brains were placed in a 
solution of Li2CO3 (11 mM) in ethanol (40%, 25 mL) and the vial containing the brains in the 
Li2CO3 solution was rotated. The solution of Li2CO3 was changed after 6 and 24 h, and the 
differentiation was continued for total of 65 h. At the end of the differentiation, the mouse brain 
was rinsed with  water (25 mL, 1 min) and hydrated in water (25 mL) for 10 min. The hydrated 
brain was pat dried and suspended in agarose gel (2%) for MR imaging.  
Optical Imaging. Optical images were acquired using an Olympus SZX7 (model number SZ2-
ILST) microscope (1.25× or 5.6× magnification) with an attached SPOT idea microscope camera 
(model number 27.2–3.1 MP). Differentiated section-stained mouse brain tissue samples were 
mounted on microscope slides to obtain images. En bloc-stained mouse brains were sliced (200 
µm) using the vibrotome after obtaining MR images, and the slices were mounted on microscope 
slides to obtain images. 
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MR Imaging. MR Imaging.  MRI scans were performed with a 7 T Varian small animal MRI 
scanner (299.44 MHz, 7.0 T) equipped with a 12 cm bore magnet and a 38 mm diameter 
homemade transmit/receive quadrature birdcage coil. Samples included a mouse brain stained 
with texaphyrin 3 and an unstained control mouse brain suspended in agarose. T1-maps were 
acquired at ambient temperature using a T-One by Multiple Read-Out Pulses,
133
 which is a 
Look–Locker sequence.134 At least one dummy cycle (N pulses followed by Trelax) was applied 
before the start of data acquisition.  Inversion of the longitudinal magnetization was 
accomplished using a non-selective hyperbolic secant adiabatic pulse of duration 12 ms. One 
phase-encode line of 40 small-tip-angle (approximately10° 3-lobe sinc shaped pulses) gradient-
echo images (4 ms) was acquired after each such adiabatic inversion (50 ms intervals) for a total 
recovery time of 3000 ms with a 3 s relaxation interval between each adiabatic inversion.   
Matrix size = 256×192; 32 mm
2
 field-of-view; three image slices at 0.5 mm thickness; and eight 
averages. Analysis proceeded as described previously,
135
 with a modification that is now 
described.  Because the 3 s relaxation time was not sufficient to allow the longitudinal 
magnetization to re-equilibrate after inversion, the equilibrated magnetization of the sequence 
was iteratively estimated along with the other model parameters (proton density, T1, and tip-
angle). ImageJ was used to process the R1-maps. Brightness and contrast were adjusted to 50 and 
color balance was adjusted to 244. Five regions of interest were used to calculate the percent 
increase of R1 in myelin-rich regions with respect to myelin-poor regions in the stained and 
unstained brains (Figure B.26).  The difference between the average R1 values of the regions of 
interest from myelin-rich and myelin-poor regions were used to calculate percent increase of R1. 
Laser Spray Ionization Vacuum (LSIV) Mass Spectrometric Imaging.  Mouse brain tissue 
(200 µm) mounted on microscope slide was spray coated with the matrix 2-nitrophloroglucinol 
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(2-NPG) (Alfa Aesar) using an air brush (Iwata). A commercial matrix-assisted laser desorption 
ionization (MALDI) source of a SYNAPT G2 mass spectrometer (Waters Corporation) was used 
for the imaging. The intermediate source pressure was 0.16 Torr. The laser used was an Nd:YAG 
laser (355 nm) in reflection geometry mode with a laser power of 12.5 J cm
–2
 and a firing rate of 
200 Hz. Data were acquired  in positive ion and sensitivity modes. Laserspray ionization  
settings were used and are as follows: 0 V on sample plate; 10 V “extraction”; 10 V “hexapole 
bias”; 5 V “aperture 0”. Data were processed using MassLynx version 4.1. Mass spectra were 
converted to MSI files using a MALDI Imaging Converter. The location of the signal of the 
complex was mapped using BioMAP 3.8.0.1 from Novartis Institutes for Biomedical Research, 
Basel, Switzerland. 
Results 
The design of myelin-specific contrast agents used in this research was inspired by the 
myelin-specific histology stain LFB MBS (Figure 4.1). The structural features of LFB MBS 
were mimicked to synthesize a ligand with a cavity large enough to encapsulate a Gd
III
 ion for 
efficient MRI enhancement. The mimic contains a texaphyrin, a ligand that is structurally similar 
to the phthalocyanine ligand of LFB MBS (Figure 4.1). Although it is known that LFB MBS 
interacts with myelin, the site of interaction is not well established; however, the currently 
accepted hypothesis assumes that the sulfonate groups of LFB MBS interact with myelin basic 
protein.
126
 To understand the features that are important for interaction with myelin, five Gd
III
-
containing texaphyrins that vary in functional group identity were synthesized (2.2–2.6 in Figure 
4.1).   
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Figure 4.1. Chemical structures of LFB MBS and Gd
III
-texaphyrin complexes 2.2–2.6.   
 
 
 
 
 
 
 
 
 
 
The functional groups introduced to the texaphyrin periphery include sulfonates, 
carboxylates, and methyl esters. Although many texaphyrin derivatives have been reported, 
texaphyrins 2.2–2.6 were new derivatives. Sulfonates and carboxylates were used to test the 
importance of the identity of acidic functional groups for interaction with myelin, and methyl 
esters were used as a control to study the need of acid functional groups. Incorporation of 
different types and numbers of functional groups into the periphery of texaphyrins resulted in 
different physicochemical properties including polarity and solubility.  
 
Solubility of texaphyrins 2.2–2.6 
The solubilities of texaphyrins 2.2–2.6 after the preparation of stain solutions are 
described here. Complexes 2.2, 2.3, and 2.4 were sparingly soluble in water but soluble in 
methanol, ethanol, and acetonitrile, while complexes 2.5 and 2.6 were soluble in water. 
Texaphyrins 2.2 and 2.4–2.6 were soluble in mixtures of water and these organic solvents and 
solutions of 2.2 and 2.4–2.6 did not yield precipitate after 3 months; however, texaphyrin 2.3 
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produced an insoluble precipitate in the presence of 95% ethanol 15 min after dissolution. The 
use of absolute ethanol avoided the rapid precipitation of 2.3, but upon storage, precipitation was 
observed after 2 days. Therefore, stain 2.3 was prepared fresh for each experiment.   
 
Properties of texaphyrins 2.2–2.6 that are important for imaging 
The extended conjugation of texaphyrins produces a characteristic sharp absorption in the 
visible region that causes the metal complexes to appear dark green in color. All five texaphyrin 
complexes demonstrated similar absorptions (Figure B.5) regardless of the number or type of the 
functional groups on the side chains. The deep green color of the texaphyrin complexes enabled 
the visualization with light microscopy similar to the visualization of the blue histology stain 
LFB MBS. The fluorescence emissions of the five complexes were also similar to each other 
regardless of functional group identity (Figures B.6 and B.7), exhibiting near-IR emission when 
excited by 468–492 nm light.  
The efficiency of complexes 2.2–2.6 as contrast agents for MRI was determined by 
measuring their relaxivities at 1.4 T and 37 °C using solvent systems that permit sufficient 
solubility for the complex. The solvent system that was used for the dissolution of the complex 
was measured as the blank in each case. All five complexes demonstrated higher relaxivity 
values than current clinical contrast agents for MRI (Table 4.1, Tables B1–15, and Figures B.8–
B.22). Texaphyrin 2.2 had the highest relaxivity (19.5 mM
–1
 s
–1
) and was similar to other 
reported texaphyrins with neutral functional group-containing side chains.
136
 Texaphyrins 2.3–
2.6 that contain negatively charged acidic functional groups in their side chains demonstrated 
lower relaxivities than 2.2, but more than 3-fold higher values than clinically approved contrast 
agents.    
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Table 4.1. Relaxivity values of texaphyrin complexes 2.2–2.6. 
Gd
III
-
texaphyrin 
complex 
2.2 2.3 2.4 2.5 2.6 
Relaxivity 
(mM
–1 
s
–1
) 
19.5 ± 0.1
*
 13.3 ± 0.2
*
 
 
11.6 ± 0.1
†
 
 
 
11.3 ± 0.2 
 
 
11.7 ± 0.1 
 
Relaxivity measured at 1.4 T, 37 °C, and in water or *30% or 
†
50% methanol in water. Results 
are reported as mean ± standard error of three independently prepared samples. 
 
While the electronic properties of Gd
III
 produce contrast enhancement with MRI, the 
unique isotopic distribution of Gd
III 
(Figure B.23) enables identification of Gd
III
-containing 
texaphyrins by mass spectrometry even in the presence of complex mixtures like tissue sections. 
Hence, the localization of texaphyrins in stained tissue can be mapped using mass spectrometry.  
 
Staining tissue with texaphyrins 2.2–2.6  
The staining of mouse brain tissue was performed by incubating tissue samples (200 µm 
thick) in stain solutions at 54 °C for 5 h. At the end of the incubation, a marked reduction of the 
intensity of color of the stain solution was visible, and the mouse brain sections were green. 
When comparing texaphyrin stains 2.2–2.6 to each other, the staining solution of complex 2.2 
demonstrated the lowest reduction of color after incubation and resulted in only lightly colored 
tissue. Tissue sections stained with texaphyrins 2.3–2.6 were dark green. To differentiate stained 
tissue samples, solutions of Li2CO3 were used;
 
however, the use of aqueous Li2CO3 that is used 
with LFB MBS
126 
 led to under-differentiation for tissue samples stained with texaphyrins 2.3 
and 2.4 and over-differentiation for texaphyrins 2.5 and 2.6. An ethanolic Li2CO3 solution was 
selected as the optimal differentiation solution because it demonstrated appreciable 
differentiation for texaphyrins 2.3–2.6.  
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Texaphyrin 2.2 that contains methyl esters did not differentiate with aqueous or ethanolic 
Li2CO3. Because of the inability to differentiate myelinated and non-myelinated regions with 
texaphyrin 2.2, it was not used for further studies.Texaphyrins 2.3 and 2.4 provided a visible 
differentiation of myelinated regions from non-myelinated regions, and texaphyrins 2.5 and 2.6 
were removed completely from tissue upon exposure to water. The removal of stain with 
exposure to water likely due to the increased hydrophilicity from presence of three or more 
negatively charged sulfonate groups and is an undesirable feature for ex vivo staining of myelin. 
In contrast, texaphyrins 2.3 and 2.4 differentiated with ethanolic Li2CO3 and were stable upon 
exposure to water; thus, texaphyrins 2.3 and 2.4 were found to be viable candidates for staining 
myelin. Myelin-rich white matter regions demonstrated a green color with respect to myelin-poor 
surrounding tissues in coronal brain sections with light microscopy when stained with 
texaphyrins 2.3 and 2.4.  Specifically, the myelin-rich corpus callosum, striations in the caudate 
putamen, anterior commissure, and mammillothalamic tract appeared green in the optical images 
(Figures 4.2, and 4.3).  
Texaphyrin 2.4 was used for staining intact mouse brains for MRI studies because of its 
ability to differentiate myelinated structures and the ease of handling without precipitation. 
When staining intact brains, the optimal incubation time for the diffusion of the texaphyrin was 
found to be 24–26 h. The diffusion of large molecules like texaphyrins takes more time for thick 
tissue samples than thin tissue sections. The differentiation time for intact brain was 65 h, and an 
incision along the mid line of the brain was made prior to differentiation to facilitate the 
diffusion of Li2CO3 into the tissue. The long differentiation times and mechanical opening of 
tissue were necessary for penetration of ionic Li2CO3 through hydrophobic tissue layers. 
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Differentiated whole mouse brain was used for MR imaging to investigate the ability of 
texaphyrin 2.4 to act as a myelin-specific contrast agent. 
 
Figure 4.2. Optical images of texaphyrin-stained mouse brain slices. Columns A–C contain 
images of representative mouse brain samples from three different regions of the brain (A, 0.50 
to 1.54; B, –1.58 to –2.18; and C, 0.14 to –0.58 mm from Bregma132) that were treated with 
texaphyrin complexes 2.2–2.6. Slice thickness = 200 µm, and scale bar = 1 mm.  
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Figure 4.3. Optical images of mouse brain sections stained with texaphyrin 2.4. Panel a. shows 
representative brain images from 1.54 to –1.82 mm from Bregma.132 Panel b. shows high 
magnification images of myelinated regions and the magnified area is represented with black 
squares in panel a. Myelin rich regions, namely; forceps minor of the corpus callosum in 1; 
external capsule and part of the caudate putamen in 2; fornix and anterior commissure anterior 
part in 3; and the mammillothalamic tract in 4 are highlighted in green. Slice thickness = 200 
µm, and scale bars = 1 mm. 
 
Mass spectrometric imaging of texaphyrin 2.4 stained mouse brain 
The brain sample stained with texaphyrin 2.4 was imaged with LSIV mass spectrometric 
imaging. Samples for mass spectrometric imaging were prepared by spray coating the brain 
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sections with the matrix 2-nitrophloroglucinol. Application of 2- nitrophloroglucinol facilitates 
ionization of the texaphyrin complexes. Expected m/z for intact texaphyrins were detected in the 
tissue. The regions with high relative concentrations of texaphyrins corresponded to myelin-rich 
regions of the brain sample (Figure 4.4). 
 
 
 
 
 
 
 
Figure 4.4. Left, Mouse brain atlas corresponding to a matching coronal section with prominent 
myelin-rich regions highlighted in green (adapted from reference 137); Right, LSIV mass 
spectrometric imaging of mouse brain sample stained with texaphyrin 2.4. Relative concentration 
of the texaphyrin 2.4 in myelin-rich regions is higher with respect to myelin-poor regions in the 
mass spectrometric image.  
 
MRI imaging of texaphyrin 2.4 treated mouse brain 
An intact mouse brain stained with texaphyrin 2.4 and an unstained control brain were 
embedded in agarose prior to MR imaging. The T1-maps of the mouse brains stained with 
texaphyrin 2.4 demonstrated a clear deference between myelin-rich (dark) and poor (bright) 
regions in comparison to the unstained control (Figure 4.5, a and b). Myelin-rich regions of the 
stained sample were dark because the T1-relaxation time is shorter (~400 ms) than the myelin 
poor regions (~650 ms) of the same tissue and the  T1 relaxation time of the control sample  
(myelin-rich regions ≈ 1000 ms and myelin-poor regions ≈ 1300 ms). The T1-map was converted 
into an R1-map because it is easier for visualization of regions of interest (Figure 4.5, c and d).  
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Figure 4.5. Representative T1- and R1-maps of coronal sections of mouse brains (–1.58 mm from 
Bregma)
132
: a. T1-map of unstained control brain; b. T1-map of mouse brain stained with 
texaphyrin 2.4; c. R1-map of unstained control brain; and d. R1-map of texaphyrin 2.4 stained 
mouse brain. Myelin-rich regions of stained brain sample look brighter with respect to the 
myelin-poor gray matter regions of the tissue, and myelin-rich regions of the control in the R1-
map. 
  
R1 values represent 1/T1, and short T1 values produce large R1 values thus, inverting the 
brightness of the T1-map. The R1 value of myelin-rich regions of the stained brain was ~2.6 fold 
greater than the surrounding myelin-poor tissue while the R1 value was only ~1.6 fold greater in 
the myelin rich regions of the unstained control brain. Thus, the myelin-rich regions in R1-map of 
stained brain look brighter and are easy to distinguish due to the additional contrast enhancement 
by texaphyrin 2.4 with respect to the unstained control.  At the end of the MR imaging, the brain 
sample was sectioned and observed with light microscopy and mass spectrometric imaging to 
verify the MRI and to identify the chemical identity of the Gd
III
-containing contrast agent after 
staining (Figure 4.6 and Figure B.25). 
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Figure 4.6. Optical and mass spectrometric images of coronal brain sections corresponding to 
the MR images in Figure 4.5. a. optical image of unstained control brain; b. optical image of 
brain stained with texaphyrin 2.4; c. mass spectrometric image of brain stained with texaphyrin 
2.4; d. mouse brain atlas corresponding to a matching coronal section with prominent myelin-
rich regions highlighted in green (adapted from reference 137).
 
In the image cc, CPu, f, fi, ic, 
mmt, and ot stand for corpus callossum, caudate putamen, fornix, fimbria, internal capsule, 
mammillothalamic tract, and optic tract, respectively. Red arrows point to the myelin-rich 
regions of mass spectrometric image. Scale bar = 1 mm.         
 
 
Discussion 
A well known myelin-specific histology stain LFB MBS was used as our structural 
inspiration because it contains a metal-ligand motif that is amenable to adaptation into a contrast 
agent for MRI. However, the ligand framework of LFB MBS cannot be directly used for the 
synthesis of stable Gd
III
-containing complexes because the cavity size of the phthalocyanine in 
LFB MBS does not match well with the ionic radius of Gd
III
.
138
 Sessler and co-workers  reported 
the use of expanded porphyrins known as texaphyrins to form stable complexes with 
lanthanides.
82–84, 93–95
 Their studies with Gd
III
-containing texaphyrins have shown that complexes 
of these macrocycles are efficient contrast agents for MRI and have higher relaxivities than 
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clinically approved contrast agents.
136
 Knowledge from Sessler’s studies helped to realize that 
texaphyrins have the potential to mimic the structural features of phthalocyanine— including a 
planar aromatic macrocycle, acidic functional groups, and charge—while forming stable 
complexes with Gd
III
.  Although, LFB MBS interacts with myelin, the important structural 
features for interaction are not well established. Therefore, five different texaphyrin complexes 
that vary in the type and number of functional groups on the side chains were synthesized. This 
variety was expected to enable on understanding of the structural features that lead to 
interactions with myelin. The functional groups that were selected included methyl esters, 
sulfonates, and carboxylates. Because some of these functional groups have not been reported 
with texaphyrins, synthetic routes to make them had to be devised. 
The functional group selection allowed to explore the influence of a variety of properties 
on staining. Complex 2.2 has an overall charge of +2, and it does not have acidic functional 
groups; thus, it was designed to test if negative charge or acidic functional groups are crucial for 
myelin-specific interactions. Complex 2.3 has carboxylate groups and is neutral. This complex is 
a carboxylate analogue for sulfonate containing texaphyrins and was synthesized to study the 
necessity of sulfonates as the acidic functional groups. Complexes 2.4–2.6 have sulfonate groups 
and charges of 0, –1, –2, respectively, and these complexes were designed to study the effect of 
the number of sulfonate groups on interaction with myelin. 
 Initial staining studies with coronal sections of mouse brain tissue was performed to 
visualize the interaction of texaphyrins 2.2–2.6 with myelinated structures. Brain sections stained 
with Gd
III
-containing texaphyrins were differentiated with Li2CO3 solutions to remove excess 
and loosely bound texaphyrins, under the assumption that mild alkali solutions interrupt the 
interaction between sulfonates and myelin.
126
 Because hydrophilic alkali solutions do not enter 
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the hydrophobic domains of myelin to interrupt the interactions, the stain is retained in 
myelinated structures.
126
 Because of the optical absorptions of texaphyrins,  light microscopy 
was initially used to gauge the interaction of the texaphyrins with myelin. Texaphyrin complexes 
have a characteristic dark green color due to the absorption of visible light in the 700–750 nm 
range. Thus, texaphyrins are chromophoric probes similar to LFB MBS. Additionally, the 
fluorescence emission studies demonstrated a near-IR emission and, consequently, the potential 
for use as fluorescence probes.  
Light microscopy images of mouse brain slices stained with Gd
III
-containing texaphyrins 
showed that complexes 2.3 and 2.4 that are less hydrophilic than complexes 2.5 and 2.6 
differentiate better and, consequently, highlight myelinated regions in the brain tissue more 
efficiently than the other three complexes. Texaphyrins 2.5 and 2.6 that have more than two 
negatively charged functional groups did stain myelin, but the high solubility of these 
texaphyrins in water interferes with the retention of the stain in myelinated regions. Texaphyrin 
2.2 did not highlight myelin and demonstrated non-specific staining of brain tissue. Unlike 
texaphyrins 2.3–2.6, Li2CO3 was not able to remove texaphyrin 2.2 from tissue samples. The 
observations with staining studies of texaphyrins 2.2–2.6 reveal that the presence of a negatively 
charged acidic functional group is vital for interaction with myelin. It is assumed that the 
interaction of LFB MBS and myelin occurs through an acid-base type interaction between the 
negatively charged sulfonate groups of the stain and positively charged amine residues of the 
myelin basic proteins.
126
  The observations from this research support the presence of this type of 
interaction because texaphyrin 2.2 with neutral methyl ester groups did not demonstrate myelin-
specific staining of brain tissues.  
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The non-specific labeling observed with texaphyrin 2.2 likely arises because the 
positively charged molecule interacts with negatively charged lipids in the tissue. Furthermore, 
maintaining some hydrophobicity seems to be critical to attain desirable staining and 
differentiation. A possible explanation for observations with texaphyrins 2.5 and 2.6 is that the 
hydrophilic stain is unable to enter the hydrophobic domains of the myelin sheath. Instead, these 
molecules might interact with the surface myelin basic proteins, which would make them easily 
remove upon exposure to water. 
To confirm the staining pattern observed with light microscopy and to explore the 
integrity of the chemical composition of texaphyrins after undergoing staining and 
differentiation, mass spectrometric imaging was performed with brain slices stained with 
texaphyrins 2.2–2.6. Although, mass spectrometry has been used as a tool for the 
characterization of compounds for decades, it has not been used as a tool of imaging until 
recently.
139 
Several promising imaging studies using MALDI and LSIV have been reported for 
imaging tissues via the detection of proteins or lipids.
139–141
 However, the detection of proteins 
and lipids is often difficult because of the high background present in biological samples. Thus, 
to confirm the presence of proteins or lipids of interest, a secondary mass spectrometric 
technique is usually required. But, when non-endogenous material like a contrast agent is being 
imaged, interference from background is avoided.
142
 Because of characteristic mass distribution 
of Gd
III
 with seven major isotopes (Figure B.23), the detection of Gd
III
-containing texaphyrins in 
tissue samples is straight forward. The imaging of brain samples stained with complex 2.4 was 
performed with LSIV mass spectrometry. The presence of intact metal complex in tissue samples 
indicates the robustness of the metal complex for the staining conditions. The images from brain 
tissues stained with texaphyrin 2.4 demonstrated high concentration regions that overlapped with 
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the myelin-rich structures of the mouse brain. Thus, confirming the presence of intact complex in 
the myelinated structures that were observed with optical microscopy. 
From optical microscopy, texaphyrins 2.3 and  2.4 that contain two carboxylates and 
sulfonates, respectively, demonstrated better staining of myelinated regions in brain tissues than 
texaphyrins 2.2, 2.5,  or 2.6. This observation indicates that the negatively charged functional 
groups do not need to be sulfonates. However, handling of texaphyrin 2.3 is difficult because of 
the formation of precipitate upon storage that results likely due to the oligomerization via 
bridging of carboxylates among Gd
III
.  Consequently, texaphyrin 2.4 was selected as the best 
myelin-specific texaphyrin of the five complexes for moving to staining of intact brains and 
observation with MRI.  
Texaphyrins 2.2–2.6 demonstrated 3.5–4× higher relaxivities than clinically approved 
contrast agents. These high relaxivities likely result from a combination of slow tumbling due to 
the size of the molecule and the availability of more than one site for water coordination. Higher 
relaxivity is desirable for contrast agents because it enables efficient contrast enhancement, 
which is especially important for detection of fine structures including white matter structures. 
The relaxivity of methyl ester-containing texaphyrin 2.2 is 1.8–1.5× greater than the sulfonate 
and carboxylate-containing texaphyrins 2.3–2.6, possibly because the interaction of these 
negatively charged groups with Gd
III
  causes  a reduction of the available sites for water 
coordination. Ion mobility mass spectrometric studies done with texaphyrin 2.4 have 
demonstrated two species in the mass plot with same m/z ratio but different drift times (Figure 
B.24). If negatively charged groups interact with the Gd
III
, those texaphyrins would have a more 
compact structure than texaphyrins with free side chains and will result in different drift times.   
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R1-mapping of intact mouse brain stained with texaphyrin 2.4 was performed to 
investigate the contrast enhancing properties of the complex. Myelinated regions of the R1-map 
of the brain samples stained with texaphyrin 2.4 demonstrated a faster relaxation rate (2.6-fold) 
than myelin-poor regions of the stained tissue. The enhancement of R1 of the myelin-rich regions 
from the surroundings was only 1.6-fold for the unstained control. Water protons tend to relax 
faster in the presence of paramagnetic Gd
III
 because of the magnetic inhomogeneity created by 
the Gd
III
 center. Thus, the increase of the R1 relaxation rate indicates the presence of Gd
III
. R1-
maps are useful for visualizing myelinated structures because of the presence of positive contrast 
enhancement in stained regions.   
To validate the observations from MRI studies with intact brains, the brain was sectioned 
after MR imaging and confirmed the presence of stain with optical microscopy and mass 
spectrometric imaging. White matter structures appeared green under the light microscope 
(Figure 4.6 and Figure B.25), and LSIV mass spectrometric imaging of the corresponding brain 
slice of MRI confirmed that texaphyrin 2.4 was interact and distributed in regions that showed a 
positive enhancement in R1-map (Figure 4.5). The imaging studies from orthogonal imaging 
modalities confirmed the ability of texaphyrin 2.4 to diffuse into intact mouse brains, 
differentiate to be retained specifically in myelinated regions, and to act as a multimodal imaging 
agent facilitating the visualization of white matter structures and chemical information about the 
structure of the imaging agent after staining.      
Conclusion 
 Efficient, small molecular probes for myelin were synthesized using a structure-
mimicking strategy. Ex vivo studies demonstrated that texaphyrins 2.3 and 2.4 interact with 
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myelin. The optical and magnetic properties of these texaphyrin complexes allowed the imaging 
of myelin in brain sections and intact brains using optical microscopy and MRI. Furthermore, the 
unique isotopic distribution of Gd
III
 facilitated the use of mass spectrometric imaging of myelin 
to provide chemical information regarding the imaging agent in tissue. The myelin-specific 
imaging agent 2.4 render the use of MRI, optical, and mass spectrometric imaging to study 
myelination and demyelination in mouse models of neuropathologies for pre-clinical research.    
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CHAPTER 5. Conclusions and Future Directions 
Conclusions 
A multimodal, β-amyloid-targeted contrast agent 
 A β-amyloid-targeted GdIII-containing complex was synthesized using the conjugation 
strategy in which a curcumin molecule and a derivative of a clinically approved contrast agent 
were conjugated using a short linker.
 
The conjugated complex 2.1 demonstrated a higher 
relaxivity than clinically approved contrast agents for magnetic resonance imaging (MRI). 
Furthermore, in vitro studies demonstrated that the curcumin-conjugated contrast agent 2.1 
interacts with β-amyloid aggregates resulting in a shortening of longitudinal relaxation time. 
Thus, complex 2.1 has potential to be an efficient, β-amyloid-specific contrast agent for MRI. 
Additionally, conjugated complex 2.1 exhibits fluorescence, and the both the wavelength and 
intensity of the emission of complex 2.1 change upon interaction with β-amyloid aggregates in 
vitro. Thus, this probe is multimodal allowing for validation of the presence of β-amyloid 
aggregates using orthogonal imaging modalities.   
 
A myelin-specific, multimodal imaging agent for magnetic resonance, optical, and mass 
spectrometric imaging 
  Myelin-targeted Gd
III
-containing complexes were synthesized by mimicking the 
structural features of a known myelin-specific stain, LFB MBS. The texaphyrin framework was 
used in this project because it has structural similarities to phthalocyanine and a cavity size that 
accommodates Gd
III
. Five different texaphyrins were synthesized by changing the functional 
groups of the side chains of the texaphyrins. These new complexes contained methyl esters, 
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carboxylates, and sulfonates. Ex vivo mouse brain samples were stained with these Gd
III 
texaphyrin complexes and imaged using optical microscopy, laser spray ionization vacuum mass 
spectrometric imaging, and MRI. These ex vivo imaging studies demonstrated that the acid 
functional groups containing neutral Gd
III
-containing texaphyrins have affinity toward myelin 
rich regions in the brain tissue.   
Future Directions 
Improvements in synthesis of conjugate 2.1 and modification of the structure for potentially 
interesting studies  
 In the synthesis of conjugate 2.1, improvements can be made to the synthesis of 2.1d by 
using a milder base such as K2CO3 instead of NaOMe. Initially, NaOMe was chosen to peroform 
conjugation at an enolic oxygen; however, phenol can be deprotonated using K2CO3, which is 
milder than NaOMe, and should minimize the formation of multiple conjugation products 
leading to an increased yield of desired product. Another improvement that can be made in the 
synthesis is the addition of the isothiocyanate-containing Gd
III
DTPA, 2.1f, dropwise to the basic 
curcumin solution. This will avoid lengthened exposure of the isothiocyanate group to a basic 
environment and could minimize the potential hydrolysis of isothiocyanate. 
 The effect of the structure of the conjugate 2.1 on interaction with β-amyloid aggregates 
is one of the parameter that is important to study. One of the structural features that can be easily 
changed in conjugate 2.1 is the amine linker length. Another structural feature that can be altered 
is the conjugation site. The synthesis of conjugates with different linker lengths and different 
sites of attachment will help in understanding the important factors needed to design more 
effective β-amyloid-targeted contrast agents.  The synthesis of neutral analogues of conjugate 2.1 
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is another potentially interesting study. Neutral complexes will enable the penetration of 
analogues of complex 2.1 through blood brain barrier and facilitate the in vivo imaging. Because 
the size of amyloid deposits are often microns in diameter, the use of high field MRI for β-
amyloid plaque imaging is desirable because high field strength MRI enables high resolution 
imaging. Synthesis of analogues of 2.1 with metal complexes that have a better relaxivity in high 
field strengths such as Eu
II
 cryptates is an interesting area of study to obtain contrast enhanced 
images of β-amyloid deposits at high field strengths.          
Investigation of the ability of conjugate 2.1 to modulate β-amyloid peptide aggregation   
 In vitro binding studies that were discussed in Chapter 3 demonstrated the ability of the 
curcumin moiety in conjugate 2.1 to interact with the pre-formed β-amyloid aggregates. The 
interaction of curcumin is not limited to labeling of β-amyloid plaques, but also is reported to 
disrupt the existing β-amyloid deposit and inhibit the formation of β-amyloid oligomers and 
fibrils. Because of these desirable properties, curcumin is widely studied as a potential 
therapeutic for Alzheimer’s disease.  However, the hydrophobic nature of the curcumin molecule 
renders it insoluble in aqueous solvents limiting its use. Because curcumin conjugate 2.1 is 
soluble in aqueous solutions, interacts with β-amyloid aggregates similar to free curcumin, and 
has imaging capabilities with MRI and fluorescence, it would be interesting to study the ability 
of conjugate 2.1 to modulate the aggregation of β-amyloid. This study would be interesting                             
because it would expand our understanding of the interaction between this multimodal imaging 
agent and β-amyloid and also our understanding of the positive or negative impact on the 
function of the curcumin moiety due to conjugation. Additionally, investigation of the molecular 
properties that are important for in vivo studies of the molecule, including permeability assays, 
and cell viability assays will give more insight into the use of the molecule.  
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 The ability of 2.1 to modulate the aggregation of β-amyloid peptides can be studied in the 
presence and absence of metal ions, including Cu
II
 or Zn
II
, that are relevant in Alzheimer’s 
disease. The formation of aggregates and the morphology of the formed aggregates can be 
investigated at different time points using gel electrophoresis and transmission electron 
microscope, respectively.  
Improvements of myelin targeted complexes 2.2–2.6 by changing structural features 
Studies presented in Chapter 4 revealed the necessary structural features of complexes 
2.2–2.6 to interact with myelin including acid functional groups. However, another interesting 
study would be the investigation of the length of the linker between texaphyrin and acid 
functional group. Because it is assumed that the interaction is taking place between acid 
functional groups and myelin basic protein, the feasibility of the interaction likely depends on the 
distance between the acid functional group and the metal ion. By synthesizing texaphyrin 
complexes containing different linker lengths and performing ex vivo imaging with these stains, 
the effect of chain length on interaction with myelin could be delineated. Furthermore, based on 
the relaxivity of complexes 2.2–2.6, it can be assumed that the negatively charged acid 
functional groups may coordinate to the metal center. This coordination results in a decreased 
water-coordination number and decreased relaxivity for the complex. By changing the length of 
side chains and by monitoring the relaxivity values, the interaction between the metal center and 
acid functional groups can be understood. Furthermore, 
17
O–NMR studies can be used to 
determine the water-coordination numbers of the complexes.  
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Improvements of sample preparation for MR imaging. 
 Use of agarose gel as the embedding medium for mouse brain imaging with MRI 
produces lot of background noise because of the water content in the gel. To reduce background 
noise and to obtain better images, embedding media with minimal water content should be used. 
By using perflouropolyether (Fomblin, CAS = 69991-67-9) media to embed tissue, background 
noise in MR image can be reduced.  
Potential applications of texaphyrins 2.3–2.6 in other fields 
 Texaphyrin complexes are colored compounds that absorb in the visible region. Unlike 
previously reported texaphyrins, new complexes 2.3–2.6 contain carboxylate and sulfonate 
groups in their side chains. These functional groups can potentially be used to anchor texaphyrin 
complexes on solid surfaces. Hence, the synthesis of these texaphyrins with different metal ions 
and the investigation of them as dye sensitizers for energy conversion would be an interesting 
study.         
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Figure B.1. HPLC Chromatogram of conjugate 2.1. a. detected using a photodiode array (254 
nm trace shown) and b. Detected using a fluorescence detector (λex = 395 nm and λem = 521 nm).  
a. 
b. 
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Figure B.2. HPLC Chromatogram of conjugate 2.5.  Detected using a photodiode array: a. 210 
nm and b.  476 nm traces shown. 
a. 
b. 
127 
 
             
             
             
             
             
             
  
 
 
 
 
 
 
 
Figure B.3. HPLC Chromatogram of conjugate 2.6.  Detected using a photodiode array: a. 210 
nm and b.  476 nm shown. 
 
a. 
b. 
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Figure B.4. UV-vis absorption spectra of texaphyrin ligands 2.2L, 2.4L–2.6L: 2.2L (…); 2.4L 
(=); 2.5L (· ―); and 2.6L (―). 
 
 
 
 
 
 
 
 
 
 
 
Figure B.5. UV-vis absorption spectra of texaphyrin complexes 2.2–2.6: 2.2 (…); 2.3 (---); 2.4 
(=); 2.5 (· ―); and 2.6 (―). 
 
129 
 
 
 
 
 
 
 
 
 
 
 
Figure B.6. Emission spectra of texaphyrin complexes 2.2–2.6: 2.2 (…), λex = 485 nm; 2.3 (---), 
λex = 470 nm; 2.4 (=), λex = 468 nm; 2.5 (· ―), λex = 490 nm; and 2.6 (―), λex = 492 nm. 
 
 
 
 
 
 
 
 
 
 
 
Figure B.7. Excitation spectra of texaphyrin complexes 2.2–2.6: 2.2 (…), λem = 772 nm; 2.3 (---
), λem = 767 nm; 2.4 (=), λem = 757 nm; 2.5 (· ―), λem = 775 nm; and 2.6 (―), λem = 775 nm. 
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Table B.1  Texaphyrin 2.2 relaxation time measurements (trial 1). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
 0.55 0.092 10.9 
0.28 0.176 5.68 
0.14 0.350 2.86 
0.07 0.629 1.59 
0.00 2.913 0.340 
 
Table B.2  Texaphyrin 2.2 relaxation time measurements (trial 2). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.55 0.090 11.1 
0.28 0.180 5.71 
0.14 0.346 2.87 
0.07 0.626 1.60 
0.00 2.925 0.350 
 
Table B.3  Texaphyrin 2.2 relaxation time measurements (trial 3). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.55 0.090 11.1 
0.28 0.175 5.56 
0.14 0.348 2.89 
0.07 0.624 1.60 
0.00 2.890 0.340 
 
        
 
        
 
 
 
 
Figure B.8. Relaxivity plot of 2.2 (trial 1).  Figure B.9. Relaxivity plot of 2.2 (trial 2). 
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Figure B.10. Relaxivity plot of 2.2 (trial 3). 
 
Table B.4  Texaphyrin 2.3 relaxation time measurements (trial 1). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.57 0.135 7.41 
0.29 0.253 3.95 
0.14 0.512 1.95 
0.07 0.840 1.19 
0.04 2.969 0.340 
 
Table B.5  Texaphyrin 2.3 relaxation time measurements (trial 2). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.57 0.129 7.75 
0.29 0.251 3.98 
0.14 0.490 2.04 
0.07 0.850 1.18 
0.04 2.953 0.340 
 
 
 
 
 
y = 19.63x + 0.22 
R² = 0.999 
0 
12 
0.00 0.30 0.60 
1
/T
1
 (
s–
1
) 
Concentration (mM) 
132 
 
Table B.6  Texaphyrin 2.3 relaxation time measurements (trial 3). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.57 0.129 7.75 
0.29 0.253 3.98 
0.14 0.474 2.04 
0.07 0.870 1.18 
0.04 2.940 0.340 
 
 
 
 
 
 
 
 
 
Figure B.11. Relaxivity plot of 2.3 (trial 1).    Figure B.12. Relaxivity plot of 2.3 (trial 2).  
 
 
 
 
 
 
 
 
 
Figure B.13. Relaxivity plot of 2.3 (trial 3). 
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Table B.7  Texaphyrin 2.4 relaxation time measurements (trial 1). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.22 0.344 2.91 
0.11 0.730 1.37 
0.05 1.210 0.83 
0.03 1.680 0.60 
0.00 2.810 0.360 
 
Table B.8  Texaphyrin 2.4 relaxation time measurements (trial 2). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.22 0.339 2.95 
0.11 0.730 1.37 
0.05 1.200 0.83 
0.03 1.670 0.60 
0.00 2.860 0.350 
 
Table B.9 Texaphyrin 2.4 relaxation time measurements (trial 3). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.22 0.350 2.86 
0.11 0.740 1.35 
0.05 1.190 0.84 
0.03 1.620 0.62 
0.00 2.840 0.350 
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Figure B.14. Relaxivity plot of 2.4 (trial 1).   Figure B.15. Relaxivity plot of 2.4 (trial 2). 
 
 
 
 
 
 
 
 
 
Figure B.16. Relaxivity plot of 2.4 (trial 3). 
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Table B.10 Texaphyrin 2.5 relaxation time measurements (trial 1). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.80 0.1093 9.15 
0.40 0.2184 4.58 
0.20 0.4347 2.3 
0.10 0.7392 1.35 
0.00 3.8600 0.260 
 
Table B.11 Texaphyrin 2.5 relaxation time measurements (trial 2). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.80 0.1086 9.21 
0.40 0.2200 4.55 
0.20 0.4263 2.35 
0.10 0.7370 1.36 
0.00 3.8610 0.260 
 
Table B.12 Texaphyrin 2.5 relaxation time measurements (trial 3). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
0.80 0.1043 9.59 
0.40 0.2153 4.64 
0.20 0.4244 2.36 
0.10 0.7370 1.36 
0.00 3.8420 0.260 
 
 
 
 
 
 
 
Figure B.17. Relaxivity plot of 2.5 (trial 1).  Figure B.18. Relaxivity plot of 2.5 (trial 2). 
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Figure B.18. Relaxivity plot of 2.5 (trial 2). Figure  
B.19. Relaxivity plot of 2.5 (trial 3). 
Table B.13 Texaphyrin 2.6 relaxation time measurements (trial 1). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
1.02 0.0830 12.05 
0.51 0.1463 6.83 
0.26 0.2702 3.70 
0.13 0.6137 1.63 
0.00 3.8600 0.260 
 
Table B.14 Texaphyrin 2.6 relaxation time measurements (trial 2). 
Concentration 
(mM) 
T1 (s) 1/T1 (s
–1
) 
1.02 0.0810 12.35 
0.51 0.1456 6.87 
0.26 0.2615 3.82 
0.13 0.6212 1.61 
0.00 3.8610 0.260 
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Table B.15 Texaphyrin 2.6 relaxation time measurements (trial 3). 
Concentration 
(mM) T1 (s) 1/T1 (s
–1
) 
1.02 0.0829 12.06 
0.51 0.1467 6.82 
0.26 0.2636 3.79 
0.13 0.6192 1.61 
0.00 3.8420 0.260 
 
 
 
Figure B.20. Relaxivity plot of 2.6 (trial 1).               Figure B.21. Relaxivity plot of 2.6 (trial 2). 
 
 
 
 
 
 
 
 
 
Figure B.22. Relaxivity plot of 2.6 (trial 3). 
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Figure B. 23. Isotopic distribution of  texaphyrin 2.4. The mass spectrum was obtained using 
LSIV, sample was coated with 2-NPG matrix. 
 
 
 
Figure B. 24. Ion mobility mass spectrometric studies of texaphyrin 2.4. The sample was coated 
with 2-NPG matrix and mass spectrum was obtained using LSIV. a Two dimensional ion 
mobility plot of drift time vs m/z. Bright spots highlighted by yellow circles depict the two 
signals obtained for +1 complex of 2.4 at m/z 921. b Chemical structures of two possible 
confirmations for texaphyrin 2.4. c Extracted mass spectra for the two signals. 
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Figure B. 25. Light microscopic images of coronal sections of intact mouse brain stained with 
texaphyrin 2.4. The mouse brain was sectioned after obtaining MRI to confirm stain distribution. 
Panel (a) shows representative brain images from 0.62 to –3.40 mm Bregma. Panel (b) shows 
high magnification images of myelinated regions and the magnified area is represented with a 
black square containing respective number in panel (a). Slice thickness = 200 µm, Scale Bars 
represent 1 mm. 
 
  
 
 
 
Figure B. 26. R1-maps of mouse brains stained with texaphyrin 3 and unstained control marked 
with five regions of interest that were used to calculate the enhancement of relaxation rate. 
Myelin-rich and myelin-poor regions are marked by yellow and red lines, respectively. 
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Table B. 16.  Values of regions of interest used to calculate enhancement of R1.   
Area Mean Min Max         
0.062 0.002 0.002 0.003 
Myelin-rich-
Stained       
0.391 0.002 0.002 0.003 
Myelin-rich-
Stained       
0.031 0.003 0.002 0.003 
Myelin-rich-
Stained       
0.266 0.003 0.002 0.003 
Myelin-rich-
Stained 
Avg = 
0.0026 
% increase = 
160 
Fold increase 
= 2.6 
0.469 0.003 0.002 0.003 
Myelin-rich-
Stained       
0.188 0.001 0.001 0.001 
Myelin-poor-
Stained       
0.172 0.001 0.001 0.001 
Myelin-poor-
Stained       
0.172 0.001 0.001 0.001 
Myelin-poor-
Stained       
0.281 0.001 0.001 0.001 
Myelin-poor-
Stained       
0.359 0.001 0.001 0.002 
Myelin-poor-
Stained 
Avg = 
0.001     
0.203 8.03E-04 7.24E-04 9.04E-04 
Myelin-rich-
Unstained control       
0.266 9.58E-04 8.56E-04 0.001 
Myelin-rich-
Unstained control       
0.25 9.79E-04 8.36E-04 0.001 
Myelin-rich-
Unstained control       
0.578 8.67E-04 7.19E-04 0.001 
Myelin-rich-
Unstained control       
0.016 9.43E-04 9.43E-04 9.43E-04 
Myelin-rich-
Unstained control 
Avg = 
9.1E-4 
% increase = 
61.2 
Fold increase 
= 1.61 
0.312 6.42E-04 5.98E-04 7.05E-04 
Myelin-poor-
Unstained control       
0.312 5.28E-04 4.74E-04 5.90E-04 
Myelin-poor-
Unstained control       
0.219 5.11E-04 4.76E-04 5.70E-04 
Myelin-poor-
Unstained control       
0.359 5.49E-04 5.24E-04 5.96E-04 
Myelin-poor-
Unstained control       
0.266 5.92E-04 5.26E-04 6.50E-04 
Myelin-poor-
Unstained control 
Avg = 
5.6E-4      
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APPENDIX C 
This appendix contains permissions to reproduce some of the material in this thesis from 
Bentham Science Publishers from Vithanarachchi, S. M.; Allen, M. J. Current Molecular Imaging 
2012, 1, 12–25 and from The Royal Society of Chemistry from Vithanarachchi, S. M.; Allen, M. 
J. Chem. Commun. 2013, 49, 4148–4150. 
This appendix also contains permissions obtained when writing Vithanarachchi, S. M.; 
Allen, M. J. Current Molecular Imaging 2012, 1, 12–25.  
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 The focus of the research described in this thesis is the study of chemistry relevant to 
target-specific contrast agents for magnetic resonance imaging (MRI). MRI is a widely used 
technique in diagnostic medicine and biomedical research to obtain anatomical and physiological 
details of soft tissues. Contrast agents are used to enhance the contrast of MR images by causing 
changes to the chemical environment of water molecules. Clinically approved Gd
III
-containing 
contrast agents for MRI are non-specific, and consequently, have limited utility. Target-specific 
contrast agents represent one way to circumvent this limitation. In the research described in this 
thesis, myelin and β-amyloid aggregates were selected as targets because they are important in 
diagnosing neurological diseases. The myelin-targeted complexes were designed to mimic the 
structural features of a known myelin-specific histology stain, and ex vivo mouse-brain staining 
method was developed to test these complexes. Ex vivo staining studies (optical, MRI, and mass 
spectrometry imaging) demonstrated the ability of these complexes to interact with the 
myelinated regions in mouse brain tissue. Additionally, a β-amyloid-targeted agent was 
synthesized by conjugating a Gd
III
-containing complex to curcumin. The binding ability of this 
170 
 
 
complex with in vitro β-amyloid peptide aggregates was studied using relaxation time and 
fluorescence measurements. This dissertation presents the synthesis, characterization, and in 
vitro and ex vivo imaging of these complexes. The studies using these paramagnetic metal 
complexes have the potential to enable a reliable method to observe structural changes in the 
brain. 
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